Document:

EX-10.9

 Exhibit 10.9 

CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED
MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
 MASTER CLINICAL SERVICES ACREEMENT 

This Master Clinical Services Agreement (this “Agreeme11f’), is made as of Noyember 13. 2013 (the “Effective
Date”), by and between Biogen Idec Inc., a corporation established under the laws of the Commonwealth of Massachusetts, United States of America, with its business address at 14 Cambridge Center, Cambridge, Massachusetts 02142)
(“Biogen Idec”), and DermTech International, Inc., a corporation established under the laws of State of California, United States of America, with its principal executive offices located at 11099 North Torrey Pines Road, Suite I 00, La
Jolla, California 92037 (“DermTech”) and, together with Biogen Idec, the “Parties” or each, Individually, a “Party”). 

WHEREAS, Biogen Idec may from time to time sponsor one or more pre-clinical and/or clinical studies (each a “Trial” or
collectively the “Trials”); 
 WHEREAS, DermTech is experienced in the provision of certain services in connection with
clinical trials, and employs personnel experienced in all areas required to successfully provide such services in connection with Trials; and 

WHEREAS. Biogen Idec desires DermTech to perform certain services for Biogen Idec in connection with one or more Trials and DermTech is
willing to perform such services for Biogen Idec, under the terms and conditions of this Agreement. The details of the services to be performed in connection with each Trial shall be identified in a separate appendix (each an
“Appendix” and, collectively, the “Appendices”), attached to this Agreement; 
 Now, THEREFORE, In
consideration of the mutual covenants contained in this Agreement and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Biogen Idec and DcrmTech hereby agree as follows: 

 

	I.	Performance of Seryjces and Compljance with Laws. 

 1.1 DermTech shall perform certain
services (the “Services”) and create certain deliverables (the “Deliverables”) for Biogen Idec, as described in each Appendix attached hereto, in accordance with the timelines set forth in such Appendix. To the
extent that the terms of an Appendix expressly conflict with the terms of this Agreement, the terms of this Agreement shall prevail unless the Appendix expressly states the parties intent to supersede a specific provision of this Agreement. The
terms of each Appendix are incorporated into this Agreement by reference and shall be binding upon each Party and Its respective employees, directors, officers, subcontractors, consultants, agents and representatives (together, its
“Representatives”). Each Appendix attached to this Agreement shall become effective upon execution by both Parties. 
 1.2
In performing the Services, DermTech shall comply with (a) any standard operating procedures that have been mutually agreed upon In advance by the Panics, (b) the Trial protocol, (c) written Instructions from Biogen Idec, (d) all
relevant professional standards and (e) all applicable laws, regulations and guidelines. In particular, DermTech shall al all times comply with (i) the regulations issued by the ICH on Good Clinical Practice, or an equivalent standard,
such as compliance with CUA-certified quality system, (ii) all relevant national laws, rules and regulations In relation to Good Clinical Practice, (iii) to the extent applicable, Directive 2005/28/EC, dated 8 April 2005, and
Directive 2001/20/EC, dated 4 April 2001, Identifying the principles and detailed guidelines for Good Clinical Practice, and (Iv) to the extent applicable, the U.S. Food Drug and Cosmetic Act. codified at 21 U.S.C., Chapter 9, as amended to
date, and the related regulations (the “FDCA”) (collectively, “Good Clinical Practices” or “GCP’). 

1.3 To the extent that the Services include routine and specialized clinical laboratory assessments of specimens from human clinical trials,
DermTech shall at all times maintain evidence to demonstrate quality management systems to ensure data Integrity, including result reproducibility, instrument calibrations, comparison of test results and quality assurance schemes, as applicable. In
the performance of such Services, DermTech shall follow Good Clinical Laboratory Practices (“GCLP’?. or an equivalent standard, such as compliance with CUA-certified quality system. To the extent that the Services include
pre-clinical laboratory services, DermTech shall also at all times comply with (a) the OECD Principles of Good Laboratory Practice, (b) all relevant national lows, rules and regulations in relation to Good Laboratory Practice and
(c) to the extent applicable, (i) Directive 2004/9/EC and Directive 2004/10/EC, both dated 11 February 2004 (identifying the principles of OLP). and (ii) the standards and recommendations of the U.S. Food and Drug
Administration (“FDA”) (collectively, and together with GCLP or it equivalent standard, “Good Laboratory Practices” or “GLP’). 

1.4 DermTech undertakes to report immediately to Biogen Idec any breach of OCP or OLP or facts that may lead to a potential breach of GCP, OLP
or breach of the Trial protoc-01. The responsibility for reporting serious breaches of GCP, GLP or serious breaches of the Trial protocol resides with Biogen Idec, who will notify the Competent Authority as defined under Section 4.10 within
seven (7) days of receipt of the report from DermTech. 
 1.5 DermTech acknowledges that Biogen Idec and its Affiliates (as defined in
Section 17 below) must adhere to the provisions of (i) the Bribery Act 2010 of the United Kingdom (“Bribery Act”): (ii) the 

 
Foreign Corrupt Practices Act 1977 of the United States of America, ns amended, codified at IS U.S.C. §§ 78dd- I, et seq. (“FCPA”),
and (iii) any other applicable anti-corruption legislation (together the “Applicable Antl- Corruption Legislation”). A summary of the key principles underlying the Bribery Act and the
FCPA is set out in Schedule A attached hereto. Each Party shall inform its Representatives of the provisions of the Bribery Act and the FCPA. Neither Party nor its Representatives shall engage in any activity that Is prohibited by the Applicable
Anti-Corruption Legislation, including bribery, kickbacks, payoffs or other corrupt business practices. 
 1.6 DermTech acknowledges that
Biogen Idec intends to use the results of the Services for publication and regulatory purposes, including application for marketing authorizations, and agrees that it shall perform the Services to meet the standards appropriate for such use. 

1.7 DermTech shall use only experienced and qualified personnel to perform the Services. DermTech shall use its best efforts to ensure that
its Representatives comply with all of the terms and provisions of this Agreement, and DermTech shall be held liable for all acts and omissions of its Representatives in the performance of this Agreement. 

1.8 DermTech represents that it has adequate controls to ensure data Integrity and backups for the database applications and other electronic
records systems. DermTech shall use its best efforts to maintain these controls at all times and agrees to provide copies of supporting documents to Biogen Idec upon request. 

1.9 In connection with any Services that are subject to FDA review, DermTech shall notify Biogen Idec In writing of any database application
or electronic records system to be employed prior to commencement of Services. Promptly following the receipt of such notice, Biogen Idec shall inform DermTech of Biogen ldec’s approval or rejection of DermTech’s use of such database
application or electronic records system in the performance of the Services. If Biogen Idec rejects DermTech’s use of such database application or electronic records system in the performance of the Services, DermTech and Biogen Idec shall
cooperate In good faith In connection with the Implementation by DermTech of a database application or electronic records system sufficient to meet Biogen Idec’s requirements. 

 

	2.	Payment for Services and Exoenses. 

 2.1 A budget and payment schedule for the Services
(the “Budget”) shall be Included In each Appendix to this Agreement. Services shall be billed in accordance with the payment terms outlined in the relevant Appendix. The aggregate fees and expenses payable by Biogen Idec to DermTech
for the Services shall not exceed the applicable Budget without the prior written approval of Biogen Idec. Except as otherwise agreed in the applicable Budget, DermTech shall be responsible for all costs and expenses incurred by it in providing the
Services and otherwise fulfilling its obligations under this Agreement. DermTech shall submit Invoices only after completion of the corresponding milestone(s) or fixed unit(s), ns applicable, and not more frequently than once each month, unless
otherwise authorized by Biogen Idec. Invoices shall at a minimum describe in detail the Services performed, including a description of the milestone(s) or fixed units completed, and the purchase order number provided by Biogen Idec. In the event
reimbursement for costs and expenses is sought, the Invoice shall be accompanied by supporting documentation. Biogen Idec shall pay invoices received from DermTech within forty-five (45) days of receipt. DermTech represents and warrants that
Its computation of each Budget shall be made In good faith and based on Its knowledge of the Services to be performed under this Agreement. 

2.2 Biogen Idec will not honor any invoices received more than three (3) months following completion of the Services. 

2.3 Biogen Idec shall have no obligation to pay for unscheduled tests, except for unscheduled tests requested and approved by Biogen Idec. The
fee for an unscheduled test shall not exceed the fee stated In the applicable Budget for the same or substantially similar test (or, if no such test Is included in the Budget, an amount agreed to by the Parties). 

2.4 Any retest of specimens that DemTech or Biogen Idec determines is necessary due to DermTech’s negligence in the performance of the
initial test shall be performed at no additional expense to Biogen Idec. In the event repeat testing of an original specimen is necessary, DermTech agrees to store all specimens which are stable for repeat testing for a minimum or seven
(7) days, or longer In the case of specimens which may be stored at DermTech’s premises as outlined In the applicable Appendix. 

  
 2 

 2.5 Each Party represents and warrants to the other that the payment of the fees for the
performing of the Services in connection with one or more Trials (including payments to subcontractors, consultants, or other agents working on behalf of DermTech or as part of DermTech’s Services to Biogen Idec, as applicable) (i) represents
the fair market value for the performing of the Services, (ii) has not been determined In any manner that takes Into account the volume or value of any referrals, reimbursements or business between DermTech and Biogen Idec, and (iii) is
not offered or provided, In whole or In part, with the Intent of, directly or indirectly, Implicitly or explicitly, Influencing or encouraging the recipient to purchase, prescribe ,refer, sell, arrange for the purchase or sale, or recommend
favorable formulary placement of a Biogen Idec product or as a reward for past behavior. 
  

	3.	Standards of Personnel. 

 3.1 DermTech represents and warrants that DermTech, and each
Representative assigned by DermTech to perform the Services (“Personnel”), will (i) 115 applicable, demonstrate compliance with Federal, state and local laws governing residency or registry for employment
eligibility (e.g., submission of proper documentation confirming US citizenship or legal alien status and/or INS Form 1-9), (ii) not have been convicted of any crime that reflects on the
qualifications of the individual to perform the job assignment for Biogen Idec, and (ill) not have been excluded, suspended or debarred from participation in a federal health care program In the U.S. or otherwise disqualified or excluded from
other relevant bodies or programs elsewhere or, to DermTech’s knowledge, debarred pursuant to the FDCA, or currently subject to any pending debarment or similar proceedings. DermTech agrees to immediately lnfom1 Biogen Idec in writing if
DermTech or any Personnel performing Services hereunder is debarred, disqualified or excluded from relevant bodies or If any action, suit, claim, investigation or legal or administrative proceeding is pending, or, to the best of DermTech’s
knowledge, is threatened, relating to the debarment, disqualification (or any similar regulatory action) of DermTech or any Personnel performing the Services hereunder. 

3.2 DermTech further represents and warrants that DermTech has not been debarred, disqualified or banned from conducting any of the Services
to be performed under this Agreement and Is not under investigation by any regulatory or governmental authority for debarment, disqualification or any similar regulatory action. 

3.3 Biogen Idec reserves the right to reasonably reject any Personnel assigned by DcrmTech to perform the Services. Except as set forth in
Section 3.4 below, DermTech shall propose replacement Personnel to Biogen Idec for approval, which approval shall not be unreasonably withheld, as soon 115 possible and in no case any longer than thirty (30) days thereafter. 

3.4 To the extent applicable, In accordance with the Services provided under each Appendix, DermTech shall perform the Services under the
direction of the person identified as the service manager in the relevant Appendix to this Agreement (“Service Manager”). The Service Manager shall not be replaced without Biogen ldec’s prior written consent. Upon the
reasonable request of Biogen Idec at any time, or at the request of DermTech if the Service Manager is no longer able to fulfill his or her role, DermTech shall propose a replacement. Such replacement shall be interviewed and approved by Biogen Idec
prior to assuming the role of Service Manager. DermTech agrees to propose such replacement will1in a reasonable period of time, and in no case any longer than fifteen (15) days. 

 

	4.	Confidentiality. Samples. Samples Collection Technology. 

 4.1 For the purposes of this
Agreement, the term “Confidential Information” means and includes all information or data that is (a) disclosed by or on behalf of Biogen Idec or DermTech (in such case, the “Disclosing Party”) to the other
Party (in such case, the “Receiving Party”), in connection with or by reason of the Services, whether disclosed orally or in writing, in graphic or electronic form, or observed by the Receiving Party at the Disclosing Party’s
facilities or at a meeting with the Disclosing Party’s Representatives, including, without limitation, commercial, scientific, medical and technical Information and data relating to the Disclosing Party and Its business, activities or products,
a Trial drug or a Trial, (b) created or developed In connection with the performance of the Services, including, without limitation, any Deliverables . for the purposes of this Agreement, the term “Samples” means and includes
specimens of material derived from the human body provided to DermTech by or on behalf of Biogen Idec or Investigators or subjects participating in a Trial, and “Sample Collection Technology” means and includes DermTech’s
proprietary tape strips that have a proprietary adhesive film provided to Biogen Idec for the purpose of collecting Samples. References to either Party in this Section 4 shall include references to Its Representatives. Each Party shall at all
times cause its Representatives to comply with the confidentiality obligations of this Section 4. 
 4.2 The Receiving Party shall treat all
of the Confidential Information of the Disclosing Party as the confidential and exclusive property of the Disclosing Party, and, except as expressly provided herein, shall not reveal, publish, distribute or otherwise disclose any such Confidential
Information to any third party without first obtaining the prior written consent of the Disclosing Party. The Receiving Party shall not cause or permit reverse engineering, copying, reproduction, translation or decompilation of any Confidential
Information of the Disclosing Party. 

  
 3 

 4.3 DermTech shall use the Biogen Idec Confidential Information and the Samples solely to provide
the Services. Ownership of the Samples shall at no time transfer to DermTech. DermTech shall not distribute any of the Samples to any third party without first obtaining the written consent of Biogen Idec. Biogen Idec shall use the DermTech
Confidential Information and the Snmples Collection Technology solely as necessary to receive the Services. Ownership of the Samples Collection Technology shall at no time transfer to Biogen Idec. Biogen Idec shall not distribute any of the Samples
Collection Technology (other than to third parties using Somples Collection Technology for the purpose of collecting Samples on behalf of Biogen Idec) to any third party without first obtaining the written consent of DermTech. 

4.4 DermTech shall take all reasonable steps to ensure that the Biogen Idec Confidential Information and Samples are used by DermTech or its
Representatives only on the terms of confidentiality end nonuse set forth in this Agreement. DermTech shall disclose Biogen Idec Confidential Information only to those persons within Its organization who have a need to know such Confidential
Information in the course of performance of their duties and who ore bound by o written agreement, enforceable by DermTech, to protect the confidentiality of such Confidential Information . Biogen Idec shall take oil reasonable steps to ensure that
the DermTech Confidential Information and Samples Collection Technology are used by Biogen Idec, its Representatives and third parties using Samples Collection Technology for the purpose of collecting Samples on behalf of Biogen Idec only on the
terms of confidentiality and nonuse set forth in this Agreement. Biogen Idec shall disclose DermTech Confidential Information only to those persons with in its organization who have o need to know such Confidential Information In the course of
performance of their duties and who arc bound by o written agreement, enforceable by Biogen Idec, to protect the confidentiality of such Confidential Information. 

4.5 DermTech may disclose or distribute the Biogen Idec Confidential Information and the Samples to its Representatives, but only to the
extent necessary to perform the Services. DermTech agrees that any such Representative to whom such Confidential Information is disclosed shall be advised of DermTech’s obligations under this Agreement and shall be bound by terms at least as
restrictive as the confidentiality terms hereof to protect the confidentiality of the Biogen Idec Confidential Information pursuant to (a) a written agreement with DermTech or (b) the rules and standards of professional conduct to which
such Representative is bound. Biogen Idec may disclose or distribute the DermTech Confidential Information and the Samples Collection Technology to its Representatives and to third parties using Samples Collection Technology for the purpose of
collecting Samples on behalf of Biogen Idec, but only to the extent necessary to receive the Services. Biogen Idec agrees that any such Representative and third parties to whom such Confidential Information Is disclosed shall be advised of Biogen
Idec’s obligations under this Agreement and shall be bound by terms at least as restrictive as the confidentiality terms hereof to protect the confidentiality of the DermTech Confidential Information pursuant to (o) o written agreement
with Biogen Idec or (b) the rules and standards of professional conduct to which such Representative is bound. 
 4.6 The term
Confidential Information shell not include information that the Receiving Party is able to demonstrate by competent documentary evidence: 

(8) was rightfully and fully in the Receiving Party’s possession prior to receipt from the Disclosing Party; 

(b) is now, or hereafter becomes, part of the public domain through no act or failure to act on the part of the Receiving Party or its
Representatives ; 
 (c) becomes known to the Receiving Party through disclosure by a third party lawfully having possession of such
information and lawfully empowered to disclose such Information; or 
 (d) was independently developed by the Receiving Party without the
aid, application, use or benefit of Confidential Information of the Disclosing Party. 
 4.7 The obligations of confidentiality set forth In
this Agreement shell not prohibit the Receiving Party from disclosing any port of the Confidential Information and/or Samples of the Disclosing Pony which the Receiving Party Is required by law, regulation, rule, act or order of any governmental
authority or agency to be disclosed; provided, however, that the Receiving Party gives the Disclosing Party sufficient advance written notice to permit the Disclosing Party to seek a protective order or other similar order to obtain confidential
treatment with respect to such Confidential Information end/or Samples and thereafter discloses only the minimum Confidential Information and/or the Samples required to be disclosed In order to comply. In addition, In such event, the Receiving Party
will seek assurance from the requesting Party that confidential treatment will be accorded any such Confidential Information and/or Samples the Receiving Party Is compelled to disclose. Further, the Receiving Party will not oppose action by the
Disclosing Party to obtain on appropriate protective order or other reliable assurance that confidential treatment will be accorded to the Confidential Information and/or Samples. 

4.8 Upon the earlier of (a) the termination or expiration of this Agreement or (b) the Disclosing Party’s request, the
Receiving Party shall use its best efforts to promptly (I) return to the Disclosing Party any end all parts of the Confidential Information provided by the Disclosing Party to the Receiving Party in documentary form, including all copies and
other tangible embodiments thereof made by the Receiving Party’s Representatives, and (ii) destroy all Confidential Information in Receiving Party’s possession and stored in then-

  
 4 

 
accessible electronic or other media: provided, that the Receiving Party may retain one (I) copy of the Confidential Information in Its confidential files for archival purposes, subject to
the obligations hereunder of nondisclosure and nonuse. 
 4.9 Each Party acknowledges that disclosure or distribution of the Confidential
Information, Samples or Samples Collection Technology of the other Party or use of such Confidential Information, Samples or Samples Collection Technology contrary to the provisions of this Agreement may cause irreparable harm to the other Party for
which damages at law may not be an adequate remedy, and agrees that each Party shall have, in addition to any other rights or remedies available to it at law or in equity, the right to seek (e) injunctive relief to enjoin any breach or
violation or (b) specific performance of the provisions of this Agreement prohibiting disclosure and use of Confidential Information. 

4.10 Biogen Idec shall be responsible for communicating with the European Medicines Agency (EMA), FDA and any other regulatory authorities In
any country (the “Competent Authorities”), regarding a Trlal and the results thereof, and DermTech shell not contact any Competent Authority regarding a Trial or the results thereof unless DermTech has been Instructed In writing by
Biogen Idec to do so, or as required by applicable law. 
  

	5.	Intellectual Property. 

 5.1 Ownership of all Intellectual Property Rights (os defined
below) as may come into existence under any applicable law, in relation to any and all materials, methods, data, drawings, information, reports, know-how, inventions, trade secrets, improvements, techniques and other results generated or created by
DermTech or Its Representatives in the performance of the Services or as a result of access to or use of Biogen Idec Confidential Information including products, whether independently or jointly with one or more employees of Biogen Idec or others
(the “Results”), and ownership of all documentation in which the Results are embodied, whether computerized or not (the “Documentation”’), and of all Intellectual Property Rights in such Results and
Documentation, shall vest exclusively in Biogen Idec as of the moment of creation, except as set forth in Section 5.8. To the extent legally possible and/or as legally required, DermTech hereby assigns all of its right, title and interest in
and 10 all Intellectual Property Rights, the Results and the Documentation, including all Intellectual Property Rights in such Results and Documentation to Biogen Idec, which assignment Biogen Idec hereby accepts. The foregoing shall not apply to
any processes, programs, software, means or methods Independently developed by DermTech without the use of Biogen Idec Confidential Information or developed by DermTech outside Its performance of the Services, which shall remain the sole property of
DermTech. DermTech shall promptly notify Biogen Idec of any Results that it generates or creates. As soon as DermTech creates any Documentation, DermTech will provide Biogen Idec with the original copy thereof. DcrmTech may keep copies of the
Documentation during the term of this Agreement, for the sole purpose of performing this Agreement. 
 5.2 For the purpose of this
Agreement, the term “Intellectual Property Rights” means all patents, trademarks, copyrights, neighboring rights, chip-rights, typography rights, database rights (including rights of extraction), registered and unregistered designs
and model rights, utility models, all rights to (file for protection ot) inventions, know-how and trade secrets, and all rights or forms of protection of a similar nature or having equivalent or similar effect, which may subsist anywhere In the
world, whether or not any of them are registered and including applications for registration, reissues, divisions, continuations, amendments or extensions of any of them. 

5.3 Biogen Idec shall have the exclusive right. at Its sole expense and in its sole discretion, to apply for any form of legal
protection of the Results and Documentation (or portions thereof) that it considers suitable. At Biogen Idec’s request, DermTech shall assist Biogen Idec, both during and after the termination or expiration of this Agreement, In preparing and
prosecuting patent applications and patent extensions or in obtaining or maintaining other forms of legal protection of the Intellectual Property Rights, the Results and/or the Documentation. Biogen Idec shall pay DermTech at its standard consulting
rates for the assistance provided under this Section 5.3,and shall reimburse DermTech for its reasonable out-of-pocket expenses incurred in connection therewith. 

5.4 In as far as any of the rights in Section 5.I do not automatically vest in Biogen Idec upon their creation, or such rights
vest in DermTech by operation of law or otherwise, DermTech will unconditionally transfer all the rights which it may possess in any Intellectual Property Rights, Results and any Documentation as soon as such transfer is legally possible, without
any compensation being due from Biogen Idec for such transfer, and DermTech shall undertake every action and provide all reasonable assistance which shell be necessary In order to enforce such transfer of rights. 

5.5 To the extent permitted by law, DermTech hereby waives any rights It may have under applicable low to mention its name or have it
mentioned in connection with the Results and Documentation, as well as any moral rights which It may have and any claims It may have to any financial compensation in addition to the payments agreed upon and paid under this Agreement. 

5.6 DermTech warrants that all persons employed or engaged by it to perform the Services have unconditionally assigned in advance to DermTech
any and all rights which they may have or may obtain in any Intellectual Property Rights, Results or Documentation, and that DermTech is entitled to assign such rights to Biogen Idec in accordance with this Agreement. To the extent any DcrmTech
Representative shall be entitled to any rights with regard to any Intellectual Property Rights, the Results or the Documentation during the term of this 

  
 5 

 
Agreement, DcrmTech shall ensure that the respective person or entity shall immediately and unconditionally transfer these rights to Biogen Idec, without any compensation being due from Biogen
Idec. DermTech holds Biogen Idec and its Affiliates harmless from liability for any and all damages and consequences whatsoever related to breach of the warranties in this Section 5.6, and to any action taken by DermTech Representatives who
claim to be entitled to certain rights relating to Intellectual Property Rights, Results or Documentation. 
 5.7 Nothing contained
in this Agreement shall be deemed to grant to DermTech any rights or licenses under any Results, Documentation or Intellectual Property Rights of Biogen Idec or its Affiliates at any moment in time. Except to the extent necessary to perform the
Services, any use by DermTech of any Intellectual Property Right owned by, licensed to or otherwise used by Biogen Idec or It Affiliates is strictly forbidden without Biogen Idec’s prior written consent 

5.8 Intellectual Property Rights that were (a) in existence and owned by DermTech prior to the date of this Agreement or
(b) developed by DermTech Independently from the performance of the Services or access to or knowledge of Confidential Information (“DermTech IPR”) will remain the exclusive property of DermTech. For clarity, DermTech IPR shall
include all Intellectual Property Rights covering the Samples Collection Technology and all improvements thereto made by DermTech and/or Biogen Idec in connection with this Agreement. Biogen Idec shall promptly disclose any such Improvements to
DcrmTech and hereby assigns all of Its right, title and interest in and to all Intellectual Property Rights In such Improvements to DermTech, which assignment DermTech hereby accepts. DermTech hereby grants to Biogen Idec a non-exclusive, perpetual,
irrevocable, royalty-free, world-wide and transferable license, with the right to sublicense, to use and exercise all DermTech IPR In the Results and Documentation for the sole purpose of exploiting the Deliverables, the Results and Documentation.
No license fee shall be payable by Biogen Idec for this license either during or after the term of this Agreement. 
 5.9 DermTech
represents and warrants that it shall not, without the appropriate consents, approvals or agreements, (a) use the proprietary Information of any third Party in the course of performing lite Services or (b) disclose any such information to
Biogen Idec. 
  

	6.	Warranty for Services. 

 6.1 DermTech represents and warrants that the Services shall be
performed and Deliverables shall be created in a good, professional and workmanlike manner, and shall conform In all respects to the specifications set forth In the applicable Appendix, and that Its performance of the Services and creation of the
Deliverables shall be In compliance with all federal, state and local laws and regulations applicable to Its performance of the Services. Unless otherwise specified In an Appendix, DermTech agrees to promptly correct, at no cost to Biogen Idec, any
Deliverable or Service not in compliance with this warranty by either re· performing such nonconforming Service or recreating any nonconforming Deliverable within thirty (30) days of receiving written notice of such nonconformity from
Biogen Idec, or by refunding to Biogen Idec any amounts expended on such nonconforming Services or Deliverables. 
 6.2 DcrmTech represents
and warrants that all Deliverables shall be delivered free of any claim of infringement of any patent, trade secret, copyright, trademark or any other proprietary right of any person. If any Deliverable is, or in DermTech ‘s opinion Is likely
to be, determined to be infringing, DermTech shall at Its expense and option either (a) procure the right for Biogen Idec to continue using It.(b) replace it with a non· infringing equivalent, (c) modify It to make it non-infringing
, or (d) direct the return of the Infringing Deliverable and refund to Biogen Idec the fees paid for such Deliverable less a reasonable an10unt for Biogen Idec’s use of the Deliverable up to the time of return. 

 

	7.	Publication and Publicity. 

 7.1 DermTech shall not publish any articles or make any
presentations relating to the Services or referring to any data, Information or materials generated as part of the Services, in whole or in part, without the prior written consent of Biogen Idec. 

7.2 Except as required by law, neither Party shall use the name of the other Party In connection with any notification, publication, publicity
or advertising without the other Party’s prior written consent, except to advisors (including financial advisors, attorneys and accountants), potential and existing investors, and others on a need to know basis, In each case under circumstances
that reasonably protect the confidentiality thereof, or to the extent required by applicable law. 
  

	8.	Record Storage. 

 8.1 During the term of this Agreement, DermTech shall maintain all
materials and all other data obtained or generated by DermTech In the course of providing the Services, including all computerized records and files, in a secure area reasonably protected from fire, theft and destruction. At the expiration or
termination of this Agreement and upon the written request of Biogen Idec, all materials, data and information then in possession of DcrmTech and obtained or generated by DermTech in the course of providing the Services shall, at Biogen Idec’s
option, be (a) delivered to Biogen Idec at the address set forth in the applicable Appendix or to such other entity or address as Biogen Idec may specify in such request, or (b) retained by DermTech for a period of five (5) years from
the completion of the Services or such longer period required by applicable laws 

  
 6 

 
and regulations. Upon termination of this Agreement, storage, destruction, shipping and other services relating lo final record storage will be billed as pass-through costs to Biogen Idec. Biogen
Idec shall have sole responsibility for the costs of shipping materials under this Section 8. In no event shall DcrmTech dispose of any materials, data or other Information obtained or generated by DcrmTech in the course of providing the
Services without first giving Biogen Idec sixty·(60) days’ prior written notice of its intent to do so. Notwithstanding the foregoing, DermTech may retain copies of any materials referred to herein as are reasonably necessary for
regulatory or insurance purposes, subject to ongoing obligations hereunder of nondisclosure and nonuse. 
  

	9.	Indemnification. 

 9.1 Biogen Idec shall Indemnify DcrmTech and Its Representatives for
any and ell damages, costs, expenses and other liabilities, Including reasonable attorneys’ fees and court costs, incurred in connection with any third party claim, action or proceeding (a“Claim”), arising from (a) any
breach by Biogen Idec of any of Its obligations, representations or warranties hereunder, or (b) any materials (including without limitation Deliverables, Results and Documentation) DermTech prepares, publishes or disseminates at the request of
Biogen Idec; provided, however that Biogen Idec shall have no obligation hereunder with respect to any Claim 10 the extent arising from the negligence or willful misconduct of DcrmTech or any of its Representatives or the breach by DermTech of any
of its obligations under this Agreement. 
 9.2 DermTech shall indemnify Biogen Idec and its Representatives for any and all damages,
costs, expenses and other liabilities, including reasonable attorneys’ fees and court costs, incurred In connection with any Claim arising from (a) any breach by DcrmTech of any of its obligations, representations or warranties hereunder,
or (b) the negligence or willful misconduct of DcrmTech or any of Its Representatives in the performance of the Services; provided, however, that DermTech shall have no obligation hereunder with respect to any Claim to the extent arising from
the negligence or willful misconduct of Biogen Idec or any of Its Representatives or the breach by Biogen Idec of any of its obligations under this Agreement. 

9.3 The indemnification obligations of each Party (the “Indemnifying Party”) are subject to the following conditions: 

(a) The Indemnifying Party shall have received prompt notice from the Party seeking to be Indemnified (the “Indemnified
Party”) of the Claim or events likely to give rise to a Claim (in any event, within sufficient time so as not to prejudice the defense of such Claim); 

(b) The Indemnifying Party shall be given the opportunity at all times to control the defense and disposition of the Claim, with the
cooperation and assistance of the Indemnified Party; provided, however, that the Indemnifying Party shall not settle any Claim with an admission of liability or wrongdoing by the Indemnified Party with such Party’s prior written consent; and

 (c) The Indemnified Party shall take all reasonable steps to mitigate the amount of any Claim. 

 

	10,	Limitation of Liability. 

 10.I Neither Party shall be liable to the other for any
special, Incidental, indirect, punitive or consequential damages (including. but not limited to, business interruption, lost business, lost profits or lost savings) that may arise in connection with the execution and/or performance of this
Agreement, even if such Party was aware or had been advised of their possible existence; provided, however, that the foregoing limitation of liability shall not apply (o) 10 damages awarded to a third party for which a Party hereunder has an
Indemnification obligation under this section or (b) In the event of damages caused by the gross negligence or Intentional misconduct of a Party. 
  

	11.	Term and Termination. 

 11.1 The term of this Agreement (the “Term”)
shall commence as of the Effective Date and end on the fifth (5th) anniversary thereof (the “Termination Date”),unless earlier terminated in accordance with this Section.
If, on the Termination Date, there are Services outstanding under one or more of the Appendices, the Term shall automatically be extended for the duration of such Services. Notwithstanding the foregoing, during such extension period, no new
Appendices shall be entered into, unless the Parties have amended the Agreement to identify a new Termination Date in accordance with Section 21.2. 

11.2 Any of the Appendices may be terminated by Biogen Idec immediately upon written notice if Biogen Idec reasonably believes that there
would be any safely risk related to or caused by the Services to be performed under the applicable Appendices. 
 11.3 This Agreement or any
of the Appendices may be terminated by either Party: 
 (a) Upon fifteen (15) days’ prior written notice if the other Party
commits a material breach of this Agreement and such breach is not remedied within such fifteen-day (15-day) period (for the sake of 

  
 7 

 
Clarity, any violation of the GCP.GLP or the Applicable Anti-Corruption Legislation, as defined above, or of any other applicable law or regulation, shall be deemed to be a material breach of
this Agreement); or 
 (b) Upon fifteen (15) days’ prior written notice if the other Party has become bankrupt, is insolvent,
dissolved or liquidated. or has made an assignment for the benefit of creditors. or if o trustee or receiver has been appointed for the other Party, for all or a substantial pan of the assets of the other Party’s property, or any case or
proceeding has been commenced or other action taken by or against the other Party in bankruptcy or seeking reorganization, liquidation, dissolution, winding-up, arrangement, composition or readjustment of its debts or any other relief under any
bankruptcy, insolvency or reorganization or other similar act of law of any jurisdiction now or hereafter In effect (any such event or proceeding, a “Bankruptcy”). 

11.4 Upon termination or expiration of this Agreement or any of the Appendices pursuant to this Section, DermTech shall cooperate with Biogen
Idec 10 provide for an orderly cessation of the Services. DermTech shall (a) perform any Services necessary in connection with the orderly wind-down of each relevant Trial in compliance with its obligations under this Agreement and any
applicable lows, regulations or guidelines, (b) promptly prepare and submit to Biogen Idec a final Invoice and reconciliation and copies of all records relating to the relevant Services, (c) deliver to Biogen Idec all data, reports and any
other Documentation produced as a result of all Services performed by DermTech, and (d) return all data and materials provided by Biogen Idec to DermTech for the conduct of the relevant Services within thirty (30) days of receipt of the
termination notice. Biogen Idec shall (i) promptly pay the final Invoices submitted to Biogen Idec under clause (b) above for Services properly rendered, and (ii) return all data and materials provided by DermTech lo Biogen Idec for the
conduct of the relevant Services (including any unused Samples Collection Technology) within thirty (30) days of receipt of the termination notice. DermTech hereby waives any retention rights in relation to the conveyance of the data and
materials regarding the Services and agrees to transfer all data and materials as requested by Biogen Idec. In the event that any termination relates solely to a single Appendix, such termination shall not affect any other Appendices then in effect
under this Agreement, unless the Parties specifically agree in writing. and this Agreement shall continue to govern such Appendices until they are terminated or DcrmTech’s performance thereunder is completed. 

11.5 Reserved. 
 11.6 Upon
receipt of any termination notice from Biogen Idec, or upon expiration of this Agreement or of any Appendix, DermTech shall use its commercially reasonable efforts to minimize costs associated with the cessation of the Services. In the event that
this Agreement or any of the Appendices is terminated by Biogen Idec without cause, DermTech will be entitled to receive payment for all Services properly performed by DermTech through the effective date of termination, or committed to any Biogen
Idec-approved subcontractors, through or after the effective date of termination: provided, however, that (o) such Services and commitments have been previously authorized in writing by Biogen Idec, (b) DermTech has properly performed the
Services and has complied with GCP and GLP and (c) DermTech justifies any such commitments that cannot be terminated. In addition, Biogen Idec shall pay all reasonable costs incurred by DermTech that arc necessary or reasonably required In
connection with the orderly cessation of the Services provided that DermTech has requested prior written approval from Biogen Idec. In the event that this Agreement, or any of the Appendices, is terminated by Biogen Idec under Section 11.3(a),
Biogen Idec shall be liable to DermTech solely for the payment of professional fees and expenses actually and reasonably incurred prior to such DermTech breach. 

11.7 Whenever payments arc milestone-based, as detailed in the relevant Appendix, and DermTech has Incurred costs toward achieving the
milestone, but the milestone is not yet completed, following termination of this Agreement or an Appendix hereto, Biogen Idec shall pay DermTech a pro-rate portion of the fee for such milestone, based on the fixed units that have been completed ns
of the effective date of such termination, provided that such termination Is not due to the negligence, willful misconduct or material breach by DermTech. If this Agreement or an Appendix hereto Is terminated before the Services have been performed
completely, DermTech shall refund to Biogen Idec all funds advanced to DermTech for costs not yet incurred to the extent that the payments for the liabilities associated with such costs can be avoided in whole or in part. 

11.8 Biogen Idec shall not be obligated to make any final payments to DermTech until DermTech has performed all of its obligations under this
Agreement. 
 11.9 The obligations of the Parties contained in Sections 4.5, 7 to 12 and 16 to 22 of this Agreement shall survive
termination of this Agreement. 
  

	12.	Insurance. 

 12.I DermTech represents and warrants to Biogen Idec that it maintains
sufficient insurance to secure the performance of its obligations under the Agreement, Including comprehensive general liability Insurance plus Workers Compensation Insurance in the United States, or similar insurance in other countries, covering
acts or negligence of the Representatives working for DermTech within the scope of this Agreement as required by applicable law. Upon request, DermTech shall provide to Biogen Idec a certificate of insurance as evidence of such coverage. DermTech
shall maintain such coverage for the duration of this Agreement and for two (2) years thereafter. 

  
 8 

 12.2 Biogen Idec represents and warrants lo DermTech that It maintains adequate product liability
and clinical trials insurance. 
  

	13.	lndependent Contractor. 

 13.1 In connection with this Agreement, each Party Is an
independent contractor. This Agreement shall not create any relationship of employment, agency or partnership between the Parties and shall not give either Party any authority to legally bind or obligate the other Party. Neither DermTech nor any of
its Representatives shall be entitled to any benefits provided by Biogen Idec to its employees. DermTech shall be solely responsible for payment of all employment-related and compensation-reh1tcd charges and taxes associated with DermTech’s
performance of Services hereunder. 
  

	14.	Conflicts. 

 14.1 DermTech represents and warrants to Biogen Idec that its signature and
performance of this Agreement do not and will not conflict with any other agreement(s) to which DermTech is a party. DermTech warrants that, for the Term of this Agreement, it shall remain free from any commitments that would impede the completion
of the obligations hereunder. 
  

	15.	Force Majeure. 

 15.1 In the event that either Party is delayed or hindered in or
prevented from the performance of any of its obligations under this Agreement by reasons of strike, lockouts, labor troubles, inability to procure materials, failure of power, restrictive government or judicial orders or decrees, riots,
insurrection, war, acts of God, inclement weather or any similar reason or cause beyond the Party’s control, and such Party has exerted ell reasonable efforts to avoid or remedy such event, then performance of such act shall be excused for the
period of such delay; provided, however, that if such delay continues in excess of one (I) month, either Party may terminate the affected Appendices by providing written notice of such termination to the other Party. Notice of the start and
stop of any such force majeure shall be provided in writing to the other Party. 
  

	16.	Audits: Review of Work 

 16.1 Biogen Idec and its financial auditors shall have the
right, at reasonable times during normal business hours, to inspect and examine the books and records of Service Provider DermTech, to make copies of the same, and to discuss the same with appropriate officers of Service Provider DermTech to confirm
the accuracy and appropriateness of payments made by Biogen Idec hereunder. Such audits will be limited to books and records relating to the provision of the Services by Service Provider DcrmTech. 

16.2 In addition, DermTech shall permit Biogen Idec and its Representatives, during normal business hours and at mutually agreeable times, to
(a) perform quality assurance audits of the Services provided under this Agreement, record keeping procedures and storage facilities, and (b) inspect and make abstracts of records and reports collected and generated by DermTech in the
course of performing the Services to verify compliance with this Agreement, the Protocol, GCP, GLP and other applicable laws and regulations such as the Applicable Anti-Corruption Legislation, and the accuracy of information provided in connection
with the Services. DermTech shall make its Representatives reasonably available to Biogen Idec and its Representatives in order to discuss such records and reports and to resolve any questions relating to such records and reports. At the request of
Biogen Idec or its Representatives, DermTech shall immediately correct any errors or omissions In such records and reports. 
 16.3 DermTech
shall cooperate, and shall cause its Representatives, as applicable, to cooperate, with Biogen Idec and its Representatives in the event of any internal inspections or audits, upon reasonable notice and during normal business hours. DermTech shall
furthermore make available to Biogen Idec and its Representatives all Documentation, data and information relating to the Services for examination and duplication. DcrmTech shall make its Representatives available to Biogen Idec to explain and
discuss such Documentation, data and information. DermTech acknowledges and agrees that Biogen Idec may share the Results of any such audit with its partners, themselves subject to an obligation of confidentiality, whenever Services are being
provided in connection with a Trial relating to a drug which Biogen Idec develops with a partner. 
 16.4 The cost of any such audit will be
borne by Biogen Idec. 
 16.5 DcrmTech shall submit to all inquiries, audits and inspections by any relevant authorities. DermTech shall
notify Biogen Idec immediately upon receipt of notice of any inspection by any relevant authority relating to the Services, and Biogen Idec shall have the right to have a Representative of Biogen Idec present at any such inspection. DermTech shall
promptly rectify any deficiencies discovered during such inspections, audits and investigations of which DermTech is notified. 

  
 9 

	17.	Assjgnment. 

 17.1 Neither Party may assign its rights or obligations hereunder, except
that (a) either Party may assign this Agreement to a successor in interest or transferee of all or substantially all of its assets and business to which the subject matter of this Agreement relates, (b) Biogen Idec may assign Its rights
and obligations hereunder in respect of Services under this Agreement to a third party that acquires, by purchase or license, rights to further develop or commercialize the pharmaceutical, biologic or program that is the subject of such Services,
and (c) Biogen Idec may assign its rights and obligations hereunder to Its Affiliates or procure the performance by its Affiliates of some or oil of such rights and obligations, including the payment or receipt of money due hereunder, provided
that Biogen Idec shall remain jointly and severally liable to DermTech with such Affiliate for the performance of Biogen Idec’s obligations under this Agreement. 

17.2 DerrnTech shall not, at any time, subcontract oil or part of its obligations under this Agreement to any third party without the prior
written approval of Biogen Idec as to the-subcontractor, which shall not be unreasonably withheld. Any request for approval of a subcontractor shall be delivered in writing by DermTech to Biogen Idec, in accordance with Section 19, with a copy
delivered contemporaneously to the relevant Biogen Idec contract manager. DermTech shall be solely responsible for the performance of any Biogen Idec-approved subcontractors and any subcontracted Services. 

17.3 In addition to the foregoing, the Parties agree that Affiliates of Biogen Idec and/or DermTech may from time to time execute specific
Appendices with respect to particular Services and that the terms and conditions of this Agreement shall govern such Services just as if such Affiliates had been signatories to this Agreement By the execution of such Appendices, the Parties’
respective Affiliates agree for purposes of such Services to be bound by the terms and conditions of this Agreement just as if they were signatories to this Agreement, provided that the Parties shall remain responsible for the rights, obligations,
act and omissions of such Affiliates. 
 17.4 For the purposes of this Agreement, the term “Affiliates” means any person or
entity that controls or is controlled by or is under common control with Biogen Idec and/or DermTech, as the case may be. The term “Control’ means the possession, directly or indirectly, of at least fifty percent (50%) of the
share capital or voting rights or of the power to direct or cause the direction of the management and policies of an entity, whether through the ownership of voting securities, by contract or otherwise. 

 

	18.	Data Protection, 

 18.I DermTech shall comply in all material respects with the data
protection and privacy legislation in force from time to time and applicable to the provision of the Services and shall perform any registration or formalities with the local data protection authorities as required. 

18.2 Each Party shall only process personal data from the other Party or the other Party’s group companies under this Agreement in
accordance with the other Party’s Instructions. 
 18.3 Upon reasonable request by Biogen Idec, DermTech shall give Biogen Idec a copy
of all personal data from Biogen Idec and its group companies then In the possession, custody or control of DermTech in such format as Biogen Idec reasonably requires. 

18.4 DermTech acknowledges that, in accordance with the provisions of all applicable laws on the protection of individuals with regards to the
processing of personal data, Biogen Idec intends to carry out automated processing of personal data that may contain personal data relating to DermTech or Its employees, including name, field of expertise, place of work and past experience of Biogen
Idec. 
 18.S Any personal data relating to DermTech or its employees that may be contained in such processing will be processed for
purposes of the performance of this Agreement, the development of Biogen Idec activities and for communication purposes. Biogen Idec may transfer this data to Its Affiliates for purposes of the development of activities and for communication
purposes. DermTech acknowledges that some Biogen Idec Affiliates may be located in countries where the data protection standards are not as protective as in the country where DermTech or its employees usually perform their activities. 

 

	19.	Notices. 

 19.I Any notice required or permitted to be given pursuant to this Agreement
shall be in writing and shall be deemed given on the date received if delivered personally, by overnight courier service, facsimile or registered mail return receipt requested to the following address: 

 

			
	If to DermTech:	  	DermTech International, Inc.
		  	11099 North Torrey Pines Road
		  	Suite 100
		  	La Jolla, CA 92037
		  	Attn: John Dobak, M.D.

  
 10 

			
		  	         CEO and President

Tel: (8S8) 450-4222

		  	Fax: (8S8) 200-3877
		
	If to Biogen Idec:	  	Biogen Idec Inc.
		  	14 Cambridge Center
		  	Cambridge, MA 02142
		  	Attn: General Counsel
		  	Tel: (617) 679-2000
		  	Fax: (617) 679-3112
		  	[With a copy to:
		  	Vice President,
		  	Legal Chief International Counsel
		  	Tel: +41 41 39 21 700
		  	Fax: +41 41 39 21 718]

  

	20.	Governing Law. 

 20.1 This Agreement and the rights and obligations of the Parties
hereunder shall be governed by and construed in accordance with the Jaws of the Commonwealth of Massachusetts, United States of America, without reference to its choice of law principles. 

 

	20.	Entire Agreement: Amendment: Waiver. 

 20.I This Agreement, together with all Appendices
attached hereto, contains and represents the entire understanding of the Panics and supersedes all prior agreements, arrangements and communications, whether oral or written, with respect to the subject matter hereof. Each Appendix shall be a
complete statement of the relevant project terms and shall supplement the terms and conditions of this Agreement solely for the purposes of such Appendix. The terms of an Appendix may not modify or expand the express terms of this Agreement. 

21.2 No amendment, modification or supplement to this Agreement or any Appendix hereto may be made, except by means of a written document
which is signed by the authorized Representatives of the Parties. 
 21.3 The delay or failure by either Party to exercise or enforce any of
Its rights under this Agreement or any Appendix shall not constitute or be deemed to be a waiver of that Party’s right thereafter to enforce those rights, nor shall any single or partial exercise of any such rights preclude any other or further
exercise thereof or the exercise of any other right. No waiver of any provision of this Agreement or any Appendix shall be effective unless it is in writing and signed by the Party against which it is sought to be enforced. 

 

	21.	Severance. 

 22.1 If a court of competent jurisdiction holds that any term of this
Agreement is unenforceable, illegal or void, such term shall be enforced only to the extent that it is otherwise enforceable or is not in violation of such law, and all other terms of this Agreement shall remain in full force and effect. 

 

	22.	Counterparts: Sjgnatures. 

 23.1 This Agreement (a) may be executed in counterparts,
each of which shall be deemed to be an original and all of which, taken together, shall constitute a single agreement binding on all Parties, and (b) will be considered executed by a Party when the signature of such Party is delivered
physically or by email or facsimile transmission to the other Party or Parties, as appropriate. The Parties agree that any signature delivered by email or facsimile transmission shall have the some force and effect as an original signature. 

The remainder of this page is intentionally left blank. The signature page follows. 

  
 11 

 IN WITNESS WHEREOF, this Agreement has been executed by Biogen Idec and DermTech through their
duly authorized officers as of the Effective Date. 
  

									
	DERMTECH INTERNATIONAL, INC.	 		 	BIOGEN IDEC, INC.
					
	By	 	 /s/ John Dobak
	 		 	By	 	 /s/ Linda Riera

		 	John Dobak, M.D.	 		 	Name:	 	Linda Riera
		 	CEO/President	 		 	Title:	 	Director Clinical Operations

  
 12 

 Schedule A 

Bribery and Corruption 
 DermTech and Its
Representatives together with the institution, the investigator, their staff, and any other person contributing to the Trial (the Trial Parties) shall at all times in the conduct of the Trial comply with the Bribery Act 2010 of the
United Kingdom (Bribery Act), the Foreign Corrupt Practices Act 1977 of the United States of America (FCPA), and any other applicable anti-bribery and anti-corruption legislation (together the Applicable Anti-Corruption
Legislation). 
 It is the responsibility of the Trial Parties to ensure that they are familiar with, and comply with, the provisions of the Applicable
Anti-Corruption Legislation. Nevertheless, the following is intended as a summary of the key principles underlying the Bribery Act and the FCPA. 
  

	(A)	The Trial Parties must at all times act with integrity and honesty and comply with the highest ethical standards. 

  

	(B)	The Trial Parties must not make, give, or offer any payment, gift or other benefit or advantage to any person or the purposes of: 

  

	 	(i)	securing any improper advantage; or 

  

	 	(ii)	inducing the recipient or another person to do or omit to do any act in violation of their duties or responsibilities (or for the purposes of rewarding such conduct). 

This restriction applies at all times and in all contexts. For the avoidance of any doubt, it applies both to dealings with “public
officials” and to dealings with employees and agents of commercial enterprises. 
  

	(C)	Nevertheless, particular care must be exercised with dealings with public officials. The Trial Parties must not make, give or offer any payment, gift or other benefit or advantage for the purposes of influencing any act
or decision of a public official (or inducing such official to use their influence with another person, entity or government instrumentality or to affect or influence any act or decision of such other person, entity or government instrumentality).

  

	(D)	The term “public official” includes any person acting on behalf of any government department, agency or instrumentality or any state-owned or controlled enterprise. By way of example, this includes health core
professionals employed by 11 stole- or local municipality-run hospital or clinic, end representatives of public international organizations. 

  

	(E)	The Trial Parties must not make, give or offer any payment, gift or other benefit or advantage to any person whilst knowing or suspecting that all or a portion of such money, gift, benefit or advantage will be used,
whether directly or indirectly, in breach of (B) or (C) above. 

  

	(F)	The Trial Parties shall make and keep books, records, and accounts which, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Trio\ Parties. 

 

	(1)	The Trial Parties shall devise and maintain a system of internal accounting controls sufficient to provide reasonable assurances that - 

 

	 	(i)	transactions are executed in accordance with management’s general or specific authorization; 

  

	 	(ii)	transactions are recorded as necessary 

  

	 	(I)	to permit preparation of financial statements in conformity with generally accepted accounting principles or any other criteria applicable to such statements, and 

 

	 	(II)	to maintain accountability for assets: 

  

	 	(iii)	access to assets is permitted only in accordance with .management’s general or specific authorization ; and 

  

	 	(iv)	the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. 

  
 13 

 Appendix I to the Master Clinical Services Agreement, dated November 13, 2013, 

by and between Biogen Idec Inc and DermTech International, Inc. 

This Appendix I (this “Appendix”), dated November 13,2013, is subject to that certain Master Clinical Services Agreement (the
“Agreement’) dated as of November 13, 2013, by and between Biogen Idec, Inc., a corporation established under the laws of Massachusetts with its principal executive offices located at 14 Cambridge Center, Cambridge, MA 02142
(“Biogen Idec”), and DermTech International, Inc. (“DermTech’’). The terms and provisions of the Agreement are incorporated by reference into this Appendix and DermTech agrees to be bound by all other terms and
provisions of the Agreement applicable hereto. Capitalized terms used in this Appendix and not defined shall have the meanings ascribed to such terms in the Agreement. In the event of a conflict between any term of this Appendix and the Agreement,
the terms of the Agreement shall govern. 
 Trial/Programme 

999LE003 entitled: “A Pilot Study to Evaluate Using Tape Harvesting to Collect RNA from the Upper Epidermis of Healthy Volunteers and Subjects
[***]” 
 If applicable under this Appendix, test results will be forwarded to Biogen Idec or its designee no more than thirty (30) days
after delivery of a sample to DermTech, unless otherwise agreed by Biogen Idec. 
 Services 

DermTech will provide analyses of study materials to demonstrate, that non-invasive harvesting of skin samples via an adhesive patch strategy can be an
informative and reproducible method of examining gene expression in [***] skin diseases. If confirmed, this method will be used to test for drug candidate efficacy, pathway prioritization, and biomarker development and validation.
Specifically, the proposed study and related services will determine whether this DermTech technology platform can recover informative RNA from [***] lesions. Moreover, the well-established IFN signature as well as other transcripts will be
used to determine whether this technique captures the difference in the expression of RNA harvested from [***]. The expression profile obtained from the epidermis via adhesive patch harvesting will be compared to the profile obtained from
blood and from skin biopsies. 
 Itemized Services: 
  

	 	•	 	Prepare and provide adhesive patch kits by December 1, 2013 

  

	 	•	 	Assay development December 1, 2013 February 28, 2014 

  

	 	•	 	Extract RNA 

  

	 	•	 	Create cDNA 

  

	 	•	 	Provide Biogen with RNA or cDNA 

  

	 	•	 	RT qPCR analysis of target genes (Biogen to provide probe and primer LifeTech IDs) 

  

	 	•	 	Data analysis and transfer within 4 weeks of receipt of samples (two batches of 18 and 42 samples) cDNA storage for 2 years (designated Biogen freezer) 

Service Managers 
 John Alsobrook, Ph.D. and Burkhard
Jansen, M.D. 
 Payment Terms and Budget 
 Please see
attached Exhibit A for a detailed and itemized budget. 
 
 Payment term: 

Payment 1 in the amount of $[***]: Delivery of at least 30 kits to Biogen by December 01, 2013. Remaining kits (30) to be delivered to Biogen
by January 15, 2014. 
 Payment 2 in the amount of $[***] (analysis of sample batch 1 , n=18): Upon delivery of results to Biogen (approx. March
2014) 
 Payment 3 In the amount of $[***] (analysis of sample batch 2, n=42): Upon delivery of results to Biogen (approx. Oct 2014) 

Timelines are subjects to change based on enrollment rate. 
 All
invoices must include the protocol number for which Services were rendered, invoice number, P.O. number, dates of service, unit rate, number of units (if applicable) and invoice total. 

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions 

  
 1 

 DermTech shall send all invoices to: 

{US: Biogen Idec Inc. 
 Attn: Accounts Payable 

PO Box 425025 
 Cambridge, MA 02142] 

 
  

Any inquiries regarding Invoices or the status of payments may be made by contacting Biogen Idec’s Accounts Payable department by telephone at [US:
(866) 237-4946)] or by email at [finance.help@biogenidec.com] 
 Biogen Idec shall also reimburse DermTech for all reasonable
out-of-pocket_travel-related expenses necessarily, reasonably and properly incurred in the performance of the Services hereunder and previously approved in writing by Biogen Idec, payable upon Biogen Idec’s receipt of appropriate supporting
documentation. 
 If DermTech is provided with Biogen Idec equipment (office/computer equipment) for use in performance of the Services, DennTech will
return the equipment in its original condition to Biogen Idec upon completion of the Services. Biogen Idec will coordinate with DennTech the shipment and return of the equipment for purposes of proper Insurance coverage and receipt. Biogen Idec
holds the right to withhold final payment until all equipment has been returned. 
 Special Terms 

All Biogen Idec specimens received at DermTech before they are tested or processed material from the parent specimen throughout its testing life cycle will be
stored in a dedicated -80°C mechanical freezer with the following requirements: 
 Biogen Idec’s specimens will only be stored in a
Biogen Idec-owned -80°C mechanical freezer. 
 Specimens from other DermTech customers will not be permitted to be stored In the Biogen
Idec-owned freezer. 
 All Biogen Idec specimens will be inventoried so their location is tracked at all times while at DermTech. 

The preventative maintenance and service repairs of the Biogen Idec-owned freezer is the responsibility of DermTech; repair costs and costs for
potential freezer replacement will be covered by Biogen Idec. All routine preventative maintenance and any repairs will be reported to Biogen Idec during standard monthly or quarterly status reports. 

DermTech will provide the necessary back-up freezer in the event that the Biogen Idec-owned freezer fails. If the Biogen Idec-owned freezer
fails, DermTech will notify Biogen Idec within 24 hours and will provide the status of the samples and if they experienced a temperature deviation, e.g., when did the freezer, fail, what was the temperature of the failing freezer at the time the
samples were transferred and which samples were involved. This information needs to be annotated on the specimen level so that this history is tracked. 

DermTech will provide all of the necessary staff, wiring and monitoring equipment to monitor temperature of the Biogen Idec-owned freezer 24/7
365 days a year, e.g., during work hours, after work hours, holidays and weekends. 
 The set point temperature of the Biogen Idec freezer
will be -80°C. The safe operating temperature range is -80°C ± 10°C. If the freezer goes outside of this safe operating range and the freezer warms to -65°C, Biogen Idec needs to be notified within 24 hours. 

DermTech staff needs to be trained to exit the Biogen Idec freezer when the temperature raises to -72°C to avoid the freezer warming to
-70°C and warmer. 
 The remainder of this page is intentionally left blank. The signature page follows . 

  
 2 

 IN WITNESS WHEREOF, this Appendix has been executed by Biogen Idec and DermTech through their duly authorized
officers as of the date first written above. 
  

									
	DERMTECH INTERNATIONAL, INC.	 		 	BIOGEN IDEC, INC.
					
	By	 	 /s/ John Dobak
	 		 	By	 	 /s/ Linda Riera

		 	John Dobak, MD	 		 	Name:	 	Linda Riera
		 	CEO and President	 		 	Title:	 	Director Clinical Operations
					
	Date:	 	 11-18-13
	 		 		 	
					
		 		 		 		 	21NOV13

	

  
 3 

 Exhibit A 

Budget 
  

									
	 ASSAY DEVELOPMENT
	  				 			
	 64 genes
	  				 			
			
	 openarrays & reagents
	  	$	[***	] 	 			
	 lab staff time
	  	$	[***	] 	 			
	 disposables
	  	$	[***	] 	 			
		  	  
	  
	 	 	  
	  
	 
			
	 subtotal
	  	$	[***	] 	 			
		  	  
	  
	 	 	  
	  
	 
	 proj mgmnt
	  	$	[***	] 	 			
	 freezer alarm
	  	$	[***	] 	 			
		  	  
	  
	 	 	  
	  
	 
	 DEVELOPMENT TOTAL
	  	$	[***	] 	 			
		  	  
	  
	 	 	  
	  
	 
			
	 SPECIMEN TESTING
	  				 			
			
	 60 specimens total
	  				 			
	 1stbatch = 18 specimens
	  				 			
	 2nd batch = 42 specimens
	  				 			
	 all specimens tested in triplicate
	  				 			
	 specimen storage and shipping costs to be passed through to BI
	  				 			
			
	 	  	Unit	 	 	extended	 
	 adhesive patches
	  	$	[***	] 	 	$	[***	] 
	 RNA extraction
	  	$	[***	] 	 	$	[***	] 
	 cDNA synthesis
	  	$	[***	] 	 	$	[***	] 
	 rtqPCR
	  	$	[***	] 	 	$	[***	] 
	 Data analysis & transfer
	  	$	[***	] 	 	$	[***	] 
	 Disposables
	  	 	[***	] 	 	$	[***	] 
		  	  
	  
	 	 	  
	  
	 
			
	 subtotal
	  				 	$	[***	] 
		  	  
	  
	 	 	  
	  
	 
	 proj mgmnt
	  				 	$	[***	] 
		  	  
	  
	 	 	  
	  
	 
	 SPECIMEN TESTING TOTAL
	  				 	$	[***	] 
		  	  
	  
	 	 	  
	  
	 
			
	 PROJECT TOTAL
	  				 	$	[***	] 
		  	  
	  
	 	 	  
	  
	 

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions 

  
 4EX-10.1

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 Exhibit 10.1 

EXECUTION VERSION 

CONFIDENTIAL 

CO-PROMOTION AGREEMENT 

by and among 
 AMARIN
PHARMACEUTICALS IRELAND LIMITED, AMARIN PHARMA, INC. 
 and 

KOWA PHARMACEUTICALS AMERICA, INC. 

MARCH 31, 2014 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 TABLE OF CONTENTS 

 

									
	 	 	  	 	  	Page	 
			
	 	ARTICLE 1	  	  	DEFINITIONS	  	 	1	  
			
	 	ARTICLE 2	  	  	RIGHTS AND OBLIGATIONS	  	 	10	  
			
	 	2.1  	  	  	Grant of Right; Retention of Rights	  	 	10	  
	 	2.2  	  	  	Non-compete	  	 	11	  
	 	2.3  	  	  	Amarin Trademarks	  	 	11	  
	 	2.4  	  	  	Kowa Trademarks	  	 	12	  
	 	2.5  	  	  	Supply Assurance	  	 	12	  
			
	 	ARTICLE 3	  	  	GOVERNANCE	  	 	13	  
			
	 	3.1  	  	  	JSC	  	 	13	  
	 	3.2  	  	  	Responsibilities of the JSC	  	 	13	  
	 	3.3  	  	  	Major Market Events	  	 	15	  
			
	 	ARTICLE 4	  	  	PROMOTION AND DETAILING OF PRODUCT	  	 	15	  
			
	 	4.1  	  	  	Generally	  	 	15	  
	 	4.2  	  	  	Promotion Plan	  	 	15	  
	 	4.3  	  	  	Sales Representatives	  	 	16	  
	 	4.4  	  	  	Minimum Sales Support	  	 	19	  
	 	4.5  	  	  	Records and Reports	  	 	21	  
	 	4.6  	  	  	Promotional Materials	  	 	21	  
	 	4.7  	  	  	Performance Standards	  	 	22	  
	 	4.8  	  	  	Samples	  	 	22	  
	 	4.9  	  	  	No Sales or Distribution; Returns	  	 	23	  
	 	4.10	  	  	Managed Care Organizations	  	 	23	  
	 	4.11	  	  	Joint Activities	  	 	24	  
	 	4.12	  	  	Communication with Sales Representatives	  	 	24	  
	 	4.13	  	  	Prohibition on Solicitation	  	 	24	  
			
	 	ARTICLE 5	  	  	FINANCIAL PROVISIONS	  	 	24	  
			
	 	5.1  	  	  	Consideration Generally	  	 	24	  
	 	5.2  	  	  	Co-Promote Fee	  	 	24	  
	 	5.3  	  	  	Tail Period Payments	  	 	24	  
	 	5.4  	  	  	Reporting and Payment	  	 	26	  
	 	5.5  	  	  	Taxes	  	 	26	  
	 	5.6  	  	  	Costs Generally	  	 	26	  
	 	5.7  	  	  	Offset Rights	  	 	26	  
			
	 	ARTICLE 6	  	  	SUPPLY OF SAMPLES	  	 	26	  
			
	 	6.1  	  	  	Sample Ordering and Delivery	  	 	26	  
	 	6.2  	  	  	Receipt and Inspection	  	 	26	  
	 	6.3  	  	  	Sample Cost	  	 	27	  

  
 -i- 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 TABLE OF CONTENTS 

(continued) 
  

									
	 	 	  	 	  	Page	 
			
	 	ARTICLE 7	  	  	REGULATORY MATTERS, COMPLIANCE AND PHARMACOVIGILANCE	  	 	27	  
			
	 	7.1  	  	  	Responsibility	  	 	27	  
	 	7.2  	  	  	Reporting	  	 	28	  
	 	7.3  	  	  	Kowa Involvement	  	 	28	  
	 	7.4  	  	  	Regulatory Inspection or Audit	  	 	28	  
	 	7.5  	  	  	Compliance	  	 	28	  
	 	7.6  	  	  	Pharmacovigilance	  	 	30	  
	 	7.7  	  	  	Medical Inquiries	  	 	31	  
	 	7.8  	  	  	Recalls and Market Withdrawals	  	 	31	  
	 	7.9  	  	  	Reporting Responsibilities	  	 	31	  
	 	7.10	  	  	Rebate Liability	  	 	32	  
			
	 	ARTICLE 8	  	  	AUDIT RIGHTS	  	 	32	  
			
	 	ARTICLE 9	  	  	INTELLECTUAL PROPERTY	  	 	33	  
			
	 	9.1  	  	  	Ownership of Intellectual Property	  	 	33	  
	 	9.2  	  	  	Prosecution, Maintenance, Enforcement and Defense of Amarin Intellectual Property	  	 	33	  
	 	9.3  	  	  	Title to Trademarks	  	 	33	  
	 	9.4  	  	  	Protection of Trademarks	  	 	34	  
			
	 	ARTICLE 10	  	  	CONFIDENTIALITY	  	 	34	  
			
	 	10.1  	  	  	Disclosure of Know-How	  	 	34	  
	 	10.2  	  	  	Confidential Information	  	 	34	  
	 	10.3  	  	  	Disclosure to Affiliates	  	 	35	  
	 	10.4  	  	  	Press Releases and Disclosure	  	 	35	  
			
	 	ARTICLE 11	  	  	REPRESENTATIONS, WARRANTIES, COVENANTS AND INDEMNIFICATION	  	 	36	  
			
	 	11.1  	  	  	Representations and Warranties of both Parties	  	 	36	  
	 	11.2  	  	  	Additional Representations, Warranties and Covenants of Amarin	  	 	38	  
	 	11.3  	  	  	Additional Representations, Warranties and Covenants of Kowa	  	 	38	  
	 	11.4  	  	  	Indemnification by Amarin	  	 	39	  
	 	11.5  	  	  	Indemnification by Kowa	  	 	39	  
	 	11.6  	  	  	Indemnification Procedures	  	 	39	  
	 	11.7  	  	  	Limitation of Liability	  	 	40	  
	 	11.8  	  	  	Disclaimer of Warranty	  	 	40	  
	 	11.9  	  	  	Insurance	  	 	40	  

  
 -ii- 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 TABLE OF CONTENTS 

(continued) 
  

									
	 	 	  	 	  	Page	 
			
	 	ARTICLE 12	  	  	TERM AND TERMINATION	  	 	40	  
			
	 	12.1  	  	  	Term	  	 	40	  
	 	12.2  	  	  	Early Termination by Mutual Agreement	  	 	41	  
	 	12.3  	  	  	Reciprocal Early Termination Rights	  	 	41	  
	 	12.4  	  	  	Early Termination Due to Change of Control	  	 	41	  
	 	12.5  	  	  	Early Termination Due to Deficient Sales	  	 	42	  
	 	12.6  	  	  	Early Termination by Amarin	  	 	42	  
	 	12.7  	  	  	Early Termination by Kowa	  	 	42	  
			
	 	ARTICLE 13	  	  	RIGHTS AND DUTIES UPON EXPIRATION OR TERMINATION	  	 	42	  
			
	 	13.1  	  	  	Effects of Termination	  	 	42	  
	 	13.2  	  	  	Survival; Continuing Obligations	  	 	43	  
	 	13.3  	  	  	Remedies	  	 	43	  
	 	13.4  	  	  	Continuing Detailing Obligations	  	 	43	  
	 	13.5  	  	  	Tail Period Payments	  	 	43	  
			
	 	ARTICLE 14	  	  	GOVERNING LAW AND DISPUTE RESOLUTION	  	 	44	  
			
	 	14.1  	  	  	Governing Law	  	 	44	  
	 	14.2  	  	  	Dispute Resolution	  	 	44	  
	 	14.3  	  	  	Arbitration	  	 	44	  
			
	 	ARTICLE 15	  	  	MISCELLANEOUS	  	 	46	  
			
	 	15.1  	  	  	Engagement of Contract Sales Force or Subcontracting	  	 	46	  
	 	15.2  	  	  	Assignment	  	 	46	  
	 	15.3  	  	  	Notices	  	 	46	  
	 	15.4  	  	  	Force Majeure	  	 	47	  
	 	15.5  	  	  	No Partnership or Joint Venture	  	 	47	  
	 	15.6  	  	  	No Waiver Of Breach	  	 	48	  
	 	15.7  	  	  	Severability	  	 	48	  
	 	15.8  	  	  	Entire Agreement	  	 	48	  
	 	15.9  	  	  	Interpretation	  	 	48	  
	 	15.10	  	  	Execution In Counterparts	  	 	48	  
			
	 	Schedules:	  	  		  			

 Schedule 1.14 - Amarin Trademarks 

Schedule 1.53 - Kowa Trademarks 
 Schedule 1.86 - Example of
Sample Costs Calculation 
 Schedule 4.4 - PDE Adjustment Calculation Example 

Schedule 5.2 - Co-Promote Fee 

  
 -iii- 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 CO-PROMOTION AGREEMENT 

This Co-Promotion Agreement (this “Agreement”) is entered into as of March 31, 2014 (the “Effective
Date”) by and among Amarin Pharmaceuticals Ireland Limited, a company incorporated under the laws of Ireland (registered number 408912) with offices at 2 Pembroke House Upper Pembroke Street 28-32, Dublin 2, Ireland (“Amarin
Ireland”), and Amarin Pharma, Inc., a Delaware corporation with offices at 1430 Route 206 North, Suite 101, Bedminster, NJ 07921 (“Amarin Pharma”, and collectively with Amarin Ireland, “Amarin”), on the one
hand, and Kowa Pharmaceuticals America, Inc., a Delaware corporation with offices at 530 Industrial Park Blvd, Montgomery, AL 36117 (“Kowa”), on the other hand. 

RECITALS 
 WHEREAS,
Amarin Ireland owns certain intellectual property and regulatory rights relating to a drug known as Vascepa® (icosapent ethyl) capsules giving it the right to market and sell Vascepa in
the Territory; 
 WHEREAS, Amarin Ireland has granted to Amarin Pharma the right to market and sell Vascepa in the Territory;

 WHEREAS, Kowa possesses expertise in the commercialization of pharmaceutical products in the Territory and Amarin desires to
engage the services of Kowa to co-promote, and Kowa desires to co-promote, Vascepa in the Territory together with Amarin Pharma to the extent set forth herein; and 

WHEREAS, the Parties’ goal under this Agreement is to increase the sales of the Product in the Field in the Territory. 

NOW, THEREFORE, in consideration of the following mutual promises and obligations, and for other good and valuable consideration the
receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows: 
 ARTICLE 1 

DEFINITIONS 
 1.1
“Act” means the United States Federal Food, Drug and Cosmetic Act, 21 U.S.C. 301 et seq, as it may be amended from time to time, and relevant regulations and guidelines promulgated thereunder. 

1.2 “Active Moiety” means the molecule or ion, excluding those appended portions of the molecule that cause the drug
to be an ester, salt (including a salt with hydrogen or coordination bonds) or other noncovalent derivative (such as a complex, chelate, or clathrate) of the molecule, responsible for the physiological or pharmacological action of the drug
substance.  

  
 1 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 1.3 “Adverse Event” means any adverse event
associated with the use of a drug/product in humans, whether or not considered drug related, including the following: (a) an adverse event occurring in the course of the use of a drug/product in professional practice, (b) an adverse event
occurring from drug overdose whether accidental or intentional, (c) an adverse event occurring from drug abuse, (d) an adverse event occurring from drug withdrawal, or (e) any failure of expected pharmacological action. 

1.4 “Affiliate” means, in relation to a Party, any person, corporation, firm or partnership or other entity, whether
de jure or de facto, which directly or indirectly through one or more intermediaries controls, is controlled by or is under common control with such Party. An entity shall be deemed to control another entity if it: (a) owns,
directly or indirectly, more than fifty percent (50%) of the outstanding voting securities or capital stock (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) of such other
entity, or has other comparable ownership interest with respect to any entity other than a corporation, or (b) has the power, whether pursuant to contract, ownership of securities or otherwise, to direct the management and policies of such
other entity. 
 1.5 “Agreement” has the meaning set forth in the Preamble to this Agreement. 

1.6 “Amarin” has the meaning set forth in the Preamble to this Agreement. 

1.7 “Amarin Ireland” has the meaning set forth in the Preamble to this Agreement. 

1.8 “Amarin Indemnitees” has the meaning set forth in Section 11.5. 

1.9 “Amarin Intellectual Property” means Amarin Patents and Amarin Know-How. 

1.10 “Amarin Know-How” means Know-How Controlled by Amarin during the Term that (a) is relevant to this
Agreement, and (b) relates to the Product in the Field in the Territory. 
 1.11 “Amarin Patents” means
any patents or patent applications (including any substitutions, divisions, continuations, continuations-in-part, patents of addition, substitutions, registrations, reissues, re-examinations, extensions, renewals, and confirmations, and any patent
issued with respect to any such patent application) Controlled by Amarin during the Term that (a) are relevant to this Agreement, and (b) claim inventions directed to the manufacture, composition, formulation or use of the Product in the
Field in the Territory. 
 1.12 “Amarin Pharma” has the meaning set forth in the Preamble to this
Agreement. 
 1.13 “Amarin Sales Representative” means an individual employed or utilized by Amarin (for
clarity, other than a Kowa Sales Representative) who (a) engages in Detailing and other activities as a commercial pharmaceutical sales representative that are in compliance with Applicable Laws, and who is trained with respect to the Product,
including the Product Labeling and the legal use of said Product Labeling, to engage in such activities with respect to the Product in the Field in the Territory, and (b) has not been threatened with or excluded or debarred by any Regulatory
Authority. 

  
 2 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 1.14 “Amarin Trademarks” means the registered
and unregistered trademarks, trade names, logos and housemarks of Amarin and any of its Affiliates set forth on Schedule 1.14, and intellectual property rights residing in such trademarks or trade names, including copyrights and design
rights. 
 1.15 “ANCHOR Data” means data generated through conducting clinical trials that are intended to support
obtaining Regulatory Approval for the Product in the ANCHOR Indication. 
 1.16 “ANCHOR Indication” means
(a) the use of the Product as an adjunct to diet and exercise for adult patients on statin therapy with mixed dyslipidemia (one or more lipid disorders) and triglyceride levels between 200 and 499 mg/dL, or (b) such similar indication
covering the range of triglyceride levels between 200 and 499 mg/dL as it may be described in the final FDA approved Product Labeling for the Product based primarily on the ANCHOR Data. 

1.17 “Annual PDE Requirements” has the meaning set forth in Section 4.4.1(a). 

1.18 “Applicable Laws” means any and all statutes, ordinances, regulations, rules, or guidance of any kind whatsoever
and any and all requirements under permits, orders, decrees, judgments or directives and requirements of applicable Governmental Authorities, in each case pertaining to any of the activities contemplated by this Agreement, including any regulations
and guidelines promulgated by any Regulatory Authority in the Territory, all as amended from time to time. 
 1.19
“Audit” has the meaning set forth in Section 7.5.5. 
 1.20 “Benefit Plans” has the meaning
set forth in Section 4.3.5(f). 
 1.21 “Board” has the meaning set forth in Section 1.23. 

1.22 “Business Day” means a day other than a Saturday, Sunday, or a day on which banking institutions in New York, New
York are closed. 
 1.23 “Change of Control” means, with respect to a Party, any of the following events:
(a) any Third Party acquires directly or indirectly the beneficial ownership of any voting security of such Party or its controlling Affiliate representing more than fifty percent (50%) of the total voting power of the then-outstanding
voting securities of such Party or its controlling Affiliate, (b) the consummation of a merger, consolidation, recapitalization, or reorganization of such Party or its controlling Affiliate with or by a Third Party which would result in more
than fifty percent (50%) of the total voting power of the capital stock being transferred to a Third Party, or (c) a change in the composition of such Party’s, or its controlling Affiliate’s, board of directors (the
“Board”) over a period of twelve (12) consecutive months or less such that a majority of such Board’s members cease by reason of one or more contested elections for Board membership to be comprised of individuals whose
election is endorsed by a majority of the members of such Board immediately before the date of election. 

  
 3 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 1.24 “Claims” means all charges, complaints,
actions, suits, proceedings, hearings, investigations, claims, demands, judgments, orders, decrees, stipulations or injunctions. 

1.25 “Codes” mean the Code on Interactions with Healthcare Professionals promulgated by the Pharmaceutical Research
and Manufacturers of America (PhRMA) and the American Medical Association Guidelines on Gifts to Physicians, as either of the foregoing may be amended from time to time, and relevant regulations and guidelines promulgated thereunder. 

1.26 “Commercially Reasonable Efforts” means, with respect to a Party’s obligation to perform or achieve a
specified obligation for the Product or generally under this Agreement, the efforts, expertise, degree of skill, and resources that are comparable in quality and scope to those efforts, expertise, degree of skill and resources that are generally
used by such Party to perform or achieve a comparable obligation for a pharmaceutical product Controlled by such Party, which has the same regulatory requirements or status (for example, requires a prescription or is available over-the-counter), is
at a comparable stage of development or product life as the Product, and that has similar market potential as the Product, taking into account relative safety and efficacy, product profile, the competitiveness of the marketplace, relevant regulatory
circumstances, and other relevant factors, including technical, legal, scientific and/or medical factors, but, in any event, a Party’s effort shall be no less than the effort that a comparable pharmaceutical company would expend with respect to
a comparable pharmaceutical product controlled by such company taking into consideration the factors outlined above. 
 1.27
“Competing Product” means any product (other than the Product) (i) with the same Active Moiety (including drugs with the same Active Moiety included within such product as part of a drug mixture or a fixed dose combination), or
in the same class of drug (i.e., Omega-3) as the Product, or (ii) [***]. For clarity, [***] shall not be “Competing Products” for purposes of this Agreement. 

1.28 “Confidential Information” has the meaning set forth in Section 10.2. 

1.29 “Confidentiality Agreement” has the meaning set forth in Section 10.2. 

1.30 “Control” means, with respect to any Know-How, physical material, patent right, or other intellectual property
right, possession by a Party or its Affiliates (whether by ownership, license grant or other means) of the legal right to grant the right to access or use, or to grant a license or a sublicense to, such Know-How, physical material, patent right, or
other intellectual property right as provided for herein without violating the proprietary rights of any Third Party or any terms of any agreement or other arrangement between such Party (or any of its Affiliates) and any Third Party. 

1.31 “Co-Promote Fee Tail Payment” has the meaning set forth in Section 5.3.1. 

1.32 “Co-Promotion Fee” has the meaning set forth in Section 5.1. 

1.33 “Cost of Goods” means, for Product manufactured by Amarin or a Third Party, Amarin’s actual costs of
manufacturing, packaging, and testing the Product and amounts paid to a Third Party for such activities, calculated in accordance with GAAP, including: (a) the costs and expenses associated with components, such as raw materials, drugs and
chemicals, encapsulation, packaging materials and components, (b) any applicable net sales taxes, customs duties and similar import fees or costs and freight actually paid by Amarin, (c) direct production labor, (d) Third Party
logistics fees and pass-through expenses, and (e) allocated indirect and overhead charges, including insurance and internal staffing, but for clarity, excluding amortization, depreciation and other non-cash charges. Notwithstanding the
foregoing, Cost of Goods will exclude the related cost of inventory related to deferred revenue recognized for Products sold in the Territory prior to the Effective Date. 

  
 4 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 1.34 “Detail(s)” means an in-person, face to
face sales call between a Target and a Kowa Sales Representative or an Amarin Sales Representative, during which the Product’s attributes, benefits, prescribing information, and fairly balanced Safety Information are orally presented in
compliance with all Applicable Laws and with or without Promotional Materials. For clarity, (a) presentations made at conventions, exhibit booths, educational programs or speaker meetings, or similar gatherings, and (b) Sample drops (if
applicable) and reminders, shall not, in each case of clause (a) or (b), constitute a Detail. Any Details performed in a group situation or in a dinner meeting shall only be considered a single Detail regardless of the number of participants,
unless there occur in conjunction therewith one-on-one Details, in which case each such additional one-on-one Detail shall be counted each as a Detail. When used as a verb, ‘Detail’ means to engage in a Detail. 

1.35 “Dollars” means United States Dollars. 

1.36 “Effective Date” has the meaning set forth in the Preamble to this Agreement. 

1.37 “Federal Arbitration Act” has the meaning set forth in Section 14.3. 

1.38 “Field” means (a) an adjunct treatment to diet to reduce triglyceride (TG) levels in adult patients with
severe (3 500 mg/dL) hypertriglyceridemia, and (b) any other indications for which the Product is approved by the FDA for sale in the United States, including, to the extent approved by the FDA, the
ANCHOR Indication. 
 1.39 “FDA” means the United States Food and Drug Administration or any successor agency
performing comparable functions. 
 1.40 “Force Majeure” means circumstances beyond the reasonable control of
either Party, including acts of God, fires, explosions, earthquakes, floods, droughts, riots, acts of terrorism, wars, civil disturbances, sabotage, accidents, strikes or other labor disputes, unforeseen material shortages or supplier failures or
any other event or circumstance of the like of different character to the foregoing beyond the reasonable control and without the fault or negligence of a Party. 

1.41 “GAAP” means generally accepted accounting principles in the United States. 

1.42 “Governmental Authority” means any multi-national, federal, state, county, local, municipal or other governmental
authority or self-regulating organization of any nature (including any governmental division, subdivision, department, agency, bureau, branch, office, commission, council, court or other tribunal), including the FDA, the SEC and The NASDAQ Stock
Market, Inc. 

  
 5 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 1.43 “Gross Margin” means [***]. Gross Margin
shall be calculated [***]. 
 1.44 “Gross Sales” means the [***]. For the avoidance of doubt[***].
Notwithstanding the foregoing, Gross Sales will exclude [***]. 
 1.45 “Indemnitee” has the meaning set forth
in Section 11.6. 
 1.46 “Initial Term” has the meaning set forth in Section 12.1. 

1.47 “Inventions” has the meaning set forth in Section 9.1. 

1.48 “JAMS Rules” has the meaning set forth in Section 14.3. 

1.49 “Joint Steering Committee” or “JSC” means the committee established in accordance with the
procedures set forth in Section 3.1. 
 1.50 “Know-How” of a Party means all present and future information,
whether or not in written form, whether or not in the public domain and shall include biological, chemical, pharmacological, toxicological, medical or clinical, analytical, quality, manufacturing, research, or sales and marketing information,
including processes, methods, procedures, techniques, plans, programs and data. 
 1.51 “Kowa” has the
meaning set forth in the Preamble to this Agreement. 
 1.52 “Kowa Indemnitees” has the meaning set forth
Section 11.4. 
 1.53 “Kowa Sales Representative” means an individual employed by Kowa who
(a) engages in Detailing and other activities as a commercial pharmaceutical sales representative that are in compliance with Applicable Laws, and who is trained with respect to the Product, including the Product Labeling and the legal use of
said Product Labeling, to engage in such activities with respect to the Product in the Field in the Territory, and (b) has not been threatened with or excluded or debarred by any Regulatory Authority. Kowa Sales Representatives shall not engage
in medical affairs activities (including receiving, approving or delivering grants) nor will they attend formulary committee meetings and no MSL shall serve as a Kowa Sales Representative. 

1.54 “Kowa Trademarks” means the registered and unregistered trademarks, trade names, logos and housemarks of
Kowa and any of its Affiliates set forth on Schedule 1.54, and intellectual property rights residing in such trademarks or trade names, including copyrights and design rights. 

1.55 “Losses” means any and all amounts paid or payable to Third Parties with respect to a Claim of a Third Party,
together with all documented Out-of-Pocket Expenses, including attorney’s fees, reasonably incurred in complying with any judgments, orders, decrees, stipulations and injunctions that arise out of a Claim of a Third Party. 

  
 6 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 1.56 “Major Market Event” means an event
occurring after the Effective Date that materially adversely affects the market or profitability for the Product in the Territory including: [***]. For purposes of this Section 1.56, [***] means [***]. 

1.57 “Marketing Expenses” means, [***]. 

1.58 “MSL” means a medical scientific liaison who (a) conducts service based medical activities including
providing input and assistance with consultancy meetings, recommending investigators for clinical trials and providing input in the design of such trials and other research related activities, and (b) delivers non-promotional communications and
conducts non-promotional activities including reactively responding to enquiries of medical professionals for off-label information and presenting new clinical trial and other scientific information. 

1.59 “Net Sales” means [***]. 

1.60 “Net Sales Tail Payment” has the meaning set forth in Section 5.3.2, as applicable. 

1.61 “OIG” means the United States Department of Health and Human Services Office of the Inspector General.

 1.62 “OIG Guidance” has the meaning set forth in Section 7.5.2. 

1.63 “Out-of-Pocket Expenses” means expenses actually paid by a Party or its Affiliate to any Third Party. 

1.64 “Party” means Amarin or Kowa. 

1.65 “Performance Standards” has the meaning set forth in Section 4.7. 

1.66 “PDMA” means the Prescription Drug Marketing Act, and relevant regulations and guidelines promulgated
thereunder. 
 1.67 “Primary Detail” means a Detail where [***]. 

1.68 “Primary Detail Equivalent” or “PDE” means a numerical amount that scores the value of Details
performed by Kowa Sales Representatives or Amarin Sales Representatives: [***]. 
 1.69 “Product” means
(a) icosapent ethyl capsules or (b) any other preparations Controlled by Amarin containing icosapent ethyl or ethyl eicosapentaenoic acid as the only active pharmaceutical ingredient and only Active Moiety, in each case of clauses
(a) and (b), as approved by the FDA for sale in the United States and sold under either the Vascepa® trademark or another trademark Controlled by Amarin. For clarity, “Product”
does not include any product that combines icosapent ethyl or ethyl eicosapentaenoic acid with any other active pharmaceutical ingredient or Active Moiety. 

1.70 “Product Invention” has the meaning set forth in Section 9.1. 

  
 7 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 1.71 “Product Labeling” means all materials
considered labeling of a Product by the FDA from time to time, including labels and other written, printed or graphic matter located on or in (a) any container or wrapper utilized with the Product (even if not physically attached thereto), or
(b) any written material accompanying the Product, including, in each case, Product package inserts, invitations, signage, videotapes, CDs, DVDs, any other forms of electronic media, and any other format included in 21 C.F.R. 202.1(l)(2) (as
may be supplemented or amended). For purposes of this Agreement, advertising as defined in 21 C.F.R. 202.1(l)(1) (as may be supplemented or amended) is considered Product Labeling. 

1.72 “Product Launch” has the meaning set forth in Section 4.4.1. 

1.73 “Promote” means any communications or persuasive activities by or on behalf of a Party intended to increase sales
of the Product. Promotion includes activities such as distribution of Promotional Materials, Product sampling, advertising, the use of sales aids, and oral or electronic discussions with customers for the purpose of selling the Product. [***].

 1.74 “Promotion Plan” means an annual plan that sets forth: (a) the manner in which the Parties shall
deploy their respective efforts to Promote and Detail the Product in the Field in the Territory, (b) annual brand objectives, (c) tactical activities, (d) a call plan (including selection of Targets and Detailing frequency per
Target), and (e) other matters relevant to Promotion and Detailing of the Product. 
 1.75 “Promotional Activity
Data” has the meaning set forth in Section 4.5.1. 
 1.76 “Promotional Materials” means Product
Labeling that is approved by Amarin for use in connection with the Promotion and Detailing of the Product in the Field in the Territory. 

1.77 “Quarter” means, with respect to any given Year, the respective periods of three (3) consecutive
calendar months ending on March 31, June 30, September 30 or December 31; provided, however, that (a) the first calendar quarter of the Term shall extend from the Effective Date to the end of the first full
calendar quarter thereafter, and (b) the last calendar quarter of the Term shall end upon the effective date of termination or expiration of this Agreement. 

1.78 “Regulatory Approval” means all approvals or licenses necessary for the manufacture, marketing, importation,
storage and sale of the Product or a product for one or more indications in a country or regulatory jurisdiction, which may include satisfaction of all applicable regulatory and notification requirements, but which shall exclude any pricing and
reimbursement approvals. 
 1.79 “Regulatory Authority” means, in a particular country or regulatory
jurisdiction, any applicable Governmental Authority involved in granting Regulatory Approval and/or, to the extent required in such country or regulatory jurisdiction, governmental pricing or reimbursement approval of a Product in such country or
regulatory jurisdiction, including the FDA. 

  
 8 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 1.80 “Safety Information” means an Adverse Event
from any source, where the product is known and at least one demographic is known for the reporter and the patient, including: (a) an Adverse Event related to a quality defect, (b) an event during pregnancy and lactation, without an
associated Adverse Event, (c) a drug exposure via parent, (d) lack of efficacy, without an associated Adverse Event, (e) overdose (symptomatic or not), (f) interaction (symptomatic or not), (g) misuse and medication error
(symptomatic or not), (h) drug abuse, (i) unintended beneficial effects, (j) serious reports from interventional clinical trials, (k) aggregate safety reports, or (l) administration via incorrect route. 

1.81 “Sales Force SOPs” has the meaning set forth in Section 4.3.5(a). 

1.82 “Sales Quarter” has the meaning set forth in Section 4.4.1(b). 

1.83 “Sales Year” has the meaning set forth in Section 4.4.1(a). 

1.84 “Sales Representative” means a Kowa Sales Representative or an Amarin Sales Representative. 

1.85 “Sample” means a unit of prescription drug that is not intended to be sold and is intended to be distributed to a
licensed practitioner to promote the sale of the Product in the Field in the Territory in accordance with this Agreement and all Applicable Laws. 

1.86 “Sample Costs” means, for Samples manufactured by Amarin or a Third Party, Amarin’s actual costs of
manufacturing, packaging, and testing the Samples and amounts paid to a Third Party, including: (a) the costs and expenses associated with components, such as raw materials, drugs and chemicals, encapsulation, packaging materials and
components, (b) any applicable net sales taxes, customs duties and similar import fees or costs and freight actually paid by Amarin, and (c) direct production labor, all of the foregoing calculated in accordance with GAAP. Schedule
1.86 sets forth an example of the calculation of Sample Costs. 
 1.87 “SEC” means the United States Securities
and Exchange Commission or any successor. 
 1.88 “Secondary Detail” means [***]. 

1.89 “Tail Period” shall mean the period commencing on the effective date of the expiration or termination of this
Agreement and continuing until no further Tail Period Payments are due from Amarin to Kowa. The Parties acknowledge and agree that, depending on the basis for termination of this Agreement, there may be no Tail Period. 

1.90 “Tail Period Payments” means the Co-Promote Fee Tail Payment or the Net Sales Fee Tail Payment, as applicable.
The Parties acknowledge and agree that, depending on the basis for termination of this Agreement, there may be no Tail Period Payments. 

1.91 “Target” means a healthcare professional with prescribing authority in the Territory to whom a Sales
Representative Promotes the Product within applicable policy constraints and in compliance with Applicable Laws. 
 1.92
“Term” has the meaning set forth in Section 12.1. 

  
 9 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 1.93 “Territory” means the fifty
(50) United States of America, the District of Columbia and Puerto Rico. 
 1.94 “Third Party” means any
person or entity other than Amarin and Kowa or their respective Affiliates. 
 1.95 “Transition Point” means
such date and time during Year 2014 when annual Net Sales of the Product in the Field in the Territory [***], as such amount is calculated beginning on the date of Product Launch. The Parties acknowledge and agree that the Transition Point may not
occur. 
 1.96 “Year” means (a) for the first calendar year, the period commencing on the Effective Date
and ending on December 31, 2014, (b) for each successive period beginning on January 1 and ending twelve (12) consecutive calendar months later on December 31, and (c) for the calendar year in which this Agreement is
terminated, the period beginning on January 1 of such calendar year and ending on the effective date of the termination of this Agreement. 

ARTICLE 2 
 RIGHTS AND
OBLIGATIONS 
 2.1 Grant of Right; Retention of Rights. During the Term, subject to the terms and conditions of this
Agreement, Amarin Ireland hereby grants Kowa the exclusive right in the Territory to be the sole co-promoter of the Product, along with Amarin Pharma (and any contract sales force retained by Amarin in accordance with Section 15.1.2). In
connection with the foregoing, Amarin Ireland hereby covenants and agrees that it will not enforce against Kowa any of Amarin Ireland’s rights to regulatory exclusivity or under the Amarin Intellectual Property in connection with Kowa’s
performance of its obligations under this Agreement in accordance with the terms of this Agreement. Kowa shall not, and shall have no obligation or right under this Agreement to (a) Promote or Detail the Product (x) in the Territory
outside of the Field or (y) outside of the Territory or (b) sell or offer to sell the Product; provided, however, Promotion shall not be deemed to be the act of selling or offering to sell. Subject to the terms and conditions of this
Agreement, Amarin retains all other rights in and to the Product, including the right to Promote and Detail the Product in the Territory during the Term, to Promote the Product outside the Territory, and to sell and offer to sell the Product.
Subject to the terms and conditions of this Agreement, Amarin specifically retains the following rights, obligations and responsibilities with respect to the Product: 

(a) responsibility for the specifications for the Product, for the manufacture and distribution of the Product, and any future development of
the Product (including all studies and clinical trials related thereto, and related regulatory filings); 
 (b) responsibility for all
decisions regarding, and submission of, regulatory submissions, or notices of any kind, and for interactions with Governmental Authorities, including interactions arising from Kowa’s Promotion and Detailing of the Product, subject to meaningful
consultation with, and opportunity for comment by, Kowa in circumstances where such submission, notice or interaction relates directly to Kowa’s Promotion or Detailing of the Product; 

  
 10 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 (c) responsibility for creation, subsequent modification, internal
approval, and filing of all Product Labeling, Promotional Material and medical/scientific material and content (including submission of Promotional Materials to the FDA’s Office of Prescription Drug Promotion); 

(d) determining all Product pricing and positioning, including the timing of pricing changes, requests for reimbursement and the offering of
any discounts (including cash discounts with wholesalers) or rebates; 
 (e) determining the Product sampling budget, subject to meaningful
consultation with, and opportunity for comment by, Kowa (provided, that such sampling budget with respect to Samples to be distributed by Kowa shall not exceed the amount set forth in Section 4.4.1(b) without Kowa’s prior consent); 

(f) booking all Product sales; and 

(g) subject to Kowa’s obligations hereunder (or in any separate applicable agreement between the Parties), responsibility for
(A) handling all safety-related activities (including receiving all safety related complaints), (B) submitting all safety reports and interacting with Regulatory Authorities with respect thereto), (C) initiating and managing any
Product recalls, withdrawals or safety alerts, and (D) as of January 1, 2015, any investigations and notifications of “suspect or illegitimate product” (as such product is defined by the Drug Quality and Security Act (DQSA)).

 For the avoidance of doubt, Amarin retains the exclusive right to make, sell and offer to sell the Product. 

2.2 Non-compete. 

2.2.1 Obligations. Subject to Section 2.2.2, during the Term and through the end of the [***] following the effective date
of expiration or termination of this Agreement, Kowa and its Affiliates shall not, itself or with a Third Party, [***]. 
 2.2.2
[***]. 
 2.2.3 Confirmation. As a condition to receiving the Tail Period Payments, if applicable, Kowa shall submit to Amarin
on a Quarterly basis during the Tail Period a written confirmation of compliance with the terms of Section 2.2.1. 
 2.3 Amarin
Trademarks. Kowa shall have the right to use the Amarin Trademarks (i) on the Promotional Materials, training materials, Samples, or any other item provided to Kowa by Amarin in connection with Kowa’s Promotion and Detailing of the
Product in the Field in the Territory during the Term in accordance with the terms and conditions contained herein, and (ii) on Kowa’s website, or in Kowa’s promotional materials, in a manner solely intended to describe the
relationship created under this Agreement, and in all cases subject to Amarin’s prior 

  
 11 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 
review and approval of such use(s) in each new circumstance, which shall not be unreasonably withheld, conditioned or delayed. In addition, subject to Section 10.4, Kowa shall have the right
to use Amarin Trademarks otherwise only with the prior written consent of Amarin, which consent shall not be unreasonably withheld. Kowa shall not at any time during the Term do any act or thing which will in any way impair or diminish the rights of
Amarin in or to the Amarin Trademarks. All goodwill and improved reputation generated by Kowa’s use of the Amarin Trademarks shall inure to the benefit of the appropriate Amarin entity (at Amarin’s discretion), and any use of the Amarin
Trademarks by Kowa shall cease at the end of the Term. Kowa shall have no rights under this Agreement in or to the Amarin Trademarks or the goodwill pertaining thereto except as specifically provided herein. Kowa will not contest the ownership of
the Amarin Trademarks, their validity, or the validity of any registration therefor during the Term or the Tail Period. Kowa undertakes during the Term and the Tail Period not to have registered and/or not to use any marks that are confusingly
similar to the Amarin Trademarks. 
 2.4 Kowa Trademarks. Amarin shall have the right to use the Kowa Trademarks (i) on
the Promotional Materials, training materials, Samples, or any other item used Amarin by in connection with Amarin’s Promotion and Detailing of the Product in the Field in the Territory during the Term, and thereafter until such materials run
out of stock, in accordance with the terms and conditions contained herein, and (ii) on Amarin’s website, or in Amarin’s promotional materials, in a manner solely intended to describe the relationship created under this Agreement, and
in all cases subject to Kowa’s prior review and approval of such use(s) in each new circumstance, which shall not be unreasonably withheld, conditioned or delayed. In addition, subject to Section 10.4, Amarin shall have the right to use
the Kowa Trademarks otherwise only with the prior written consent of Kowa, which consent shall not be unreasonably withheld. Amarin shall not at any time during the Term do any act or thing which will in any way impair or diminish the rights of Kowa
in or to the Kowa Trademarks. All goodwill and improved reputation generated by Amarin’s use of the Kowa Trademarks shall inure to the benefit of Kowa, and any use of the Kowa Trademarks by Amarin shall cease at the end of the Term. Amarin
shall have no rights under this Agreement in or to the Kowa Trademarks or the goodwill pertaining thereto except as specifically provided herein. Amarin will not contest the ownership of the Kowa Trademarks, their validity, or the validity of any
registration therefor during the Term or the Tail Period. Amarin undertakes during the Term or the Tail Period not to have registered and/or not to use any marks that are confusingly similar to the Kowa Trademarks. 

2.5 Supply Assurance. Amarin shall use Commercially Reasonable Efforts to maintain approximately [***] of inventory of the
Product based on Amarin’s commercially reasonable forecasted demand for the Product in the Field in the Territory. In the event that Amarin’s inventory of the Product falls below such threshold, Amarin shall notify Kowa accordingly. If
Amarin subsequently experiences [***], then [***]; provided, that during the period of such stock-out, either (a) the Parties may mutually agree to terminate this Agreement in accordance with Section 12.2[***]. 

  
 12 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 ARTICLE 3 

GOVERNANCE 
 3.1
JSC. 
 3.1.1 Organization. Within twenty (20) days following the Effective Date, the Parties shall
form a JSC whose responsibility shall be to manage the day-to-day Promoting and Detailing and compliance activities of the Parties under this Agreement during the Term. The JSC shall consist of an equal number of representatives from each Party,
with at least three (3) representatives appointed by each Party. A Party may change any of its representatives on the JSC at any time with a new person (with appropriate expertise to replace the outgoing member) by giving written notice to the
other Party; provided, however, that, without limiting the generality of the foregoing, a key objective with respect to membership in the JSC shall be preserving continuity. 

3.1.2 Meetings. For the [***] following the Effective Date, the JSC shall meet on at least [***] basis (with the first meeting
being held within twenty (20) days following the Effective Date), and thereafter the JSC shall meet at least [***] every Year on a [***] basis, in each case unless a particular meeting is waived by mutual consent. In addition, each Party shall
have the right to call a meeting of the JSC on reasonable notice to the other Party. Subject to the foregoing, the JSC shall meet on such dates and at such times as agreed by the JSC and shall meet via teleconference or videoconference or, if
mutually agreed by the Parties, at a location determined by the JSC. Each Party may permit visitors with particular insights regarding the subject matter of a given JSC meeting to attend such meeting; provided, that any such visitor shall be subject
to written confidentiality and non-use obligations no less stringent than the terms of ARTICLE 10. Each Party shall be responsible for its own expenses for participating in the JSC. Meetings of the JSC will be chaired by a representative from
Amarin. Meetings of the JSC shall be effective only if at least one (1) representative of each Party is present or participating, unless otherwise agreed in writing. 

3.1.3 Minutes. Minutes of each JSC meeting will be transcribed and issued by a designee of the JSC within ten (10) Business
Days after each meeting. The minutes, if accurate, shall be approved by each Party not later than the first order of business at the immediately succeeding JSC meeting; provided, that if there is a disagreement regarding accuracy, the Parties shall
work together in good faith to resolve such disagreement and finalize such minutes as expeditiously as possible. 
 3.1.4
Decisions. The representatives of each Party serving on the JSC shall collectively have one (1) vote on all matters considered by the JSC. In the event that the JSC is unable to agree on any matter properly brought before it pursuant to
Section 3.2, such matter shall be submitted to the Chief Executive Officer of each Party, who shall attempt to reach a mutually agreed upon resolution. If no resolution is possible after a good faith effort, then Amarin shall have final
decision-making authority with respect to such dispute; provided, that Amarin shall not have the right to exercise its decision-making authority to amend this Agreement (e.g., to alter the Annual PDE Requirements under Section 4.4.1(a)). 

3.2 Responsibilities of the JSC. Except as may be otherwise expressly set forth herein, Amarin will have final planning,
oversight, performance evaluation and decision-making authority and responsibility for all sales, marketing and Promotional activities and attendant compliance activities related to the Product and Product Labeling. Notwithstanding the foregoing,
Kowa will have the opportunity, through the JSC to confer with, or recommend ideas or Promotional Materials to, Amarin regarding such sales, marketing and Promotional matters. Without limiting the rights, obligations and responsibilities expressly
reserved by Amarin under Section 2.1 (and Amarin’s decision-making authority with respect thereto), matters to come before the JSC shall be limited to the following: 

(a) Reviewing available Gross Sales, Net Sales, and other Territory-specific Product performance data as determined by the JSC; 

  
 13 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 (b) Making recommendation for new materials for commercial support and
Promotional Materials such as product detail aids, advertising, educational give-aways, speaker meetings, speaker kits and direct mail; 

(c) Reviewing Sample demand forecast; 

(d) Coordinating joint activities undertaken by the Parties in accordance with Section 4.11; 

(e) Reviewing and discussing any market research conducted by either Party with respect to the Product in the Field in the Territory; 

(f) Reviewing monthly activities of Sales Representatives; 

(g) Reviewing the efforts of Sales Representatives who engage in Detailing and other Promotional efforts with respect to the Product to
maintain desired frequency of Details and to avoid unintended duplication of Details; 
 (h) Reviewing, commenting on, and approving the
annual Promotion Plan for the Product in accordance with Section 4.2 and monitoring the implementation of the Promotion Plan; 
 (i)
Reviewing and auditing training needs and schedule, including corrective training; 
 (j) Discussing whether a Major Market Event has
occurred and making recommendations with respect thereto; 
 (k) Establishing subcommittees on an as-needed and as-appropriate basis (e.g.,
a compliance subcommittee and/or a medical activities subcommittee to oversee medical / scientific matters), overseeing the activities of all subcommittees so established, and addressing disputes or disagreements arising in all such subcommittees;

 (l) Considering and making recommendations on such other matters as are stipulated in this Agreement (e.g., non-commercial matters); and

 (m) Performing such other responsibilities as may be assigned to the JSC pursuant to this Agreement or as may be mutually agreed upon by
the Parties in writing from time to time; 

  
 14 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 provided, however, that the JSC shall have no authority to amend any provision of this
Agreement, make any binding interpretation of this Agreement, or determine whether or not a breach of this Agreement has occurred or to otherwise increase the devotion of financial or human resources of Kowa under this Agreement. 

3.3 Major Market Events. In the event of facts that may amount to a Major Market Event either Party may request that the JSC
meet within fifteen (15) days of the occurrence of such an event to discuss, in accordance with Section 3.2(j), whether a Major Market Event has occurred, to consider whether any adjustments to this Agreement should be undertaken to
address such Major Market Event (subject to amendments to this Agreement to account for any such adjustments being subject to each Party’s sole discretion and Section 15.8), and to make recommendations with respect thereto. 

ARTICLE 4 
 PROMOTION AND
DETAILING OF PRODUCT 
 4.1 Generally. Amarin hereby engages Kowa, and Kowa hereby accepts such engagement, to Promote and
Detail the Product in the Territory, subject to the terms and conditions of this Agreement. Kowa shall have no other rights relating to the Product except as specifically set forth in this Agreement. Commencing no later than [***] after the
Effective Date, in order to permit completion of Kowa’s training of Kowa Sales Representatives and other employees engaged in Promoting the Product and subject to Amarin providing such Promotional Materials (and the conversion of such
Promotional Materials from Amarin’s Apple format to Kowa’s Windows format) and training materials as Kowa reasonably requires in order to train and supply the Kowa Sales Representatives, Kowa shall deploy Kowa Sales Representatives and
such other employees to Promote and Detail the Product in the Territory in accordance with the terms of this Agreement, the Promotion Plan and the instructions of the JSC. In conducting its activities hereunder, Kowa will use Commercially Reasonable
Efforts to Promote and Detail the Product and to optimize sales of the Product in the Field during the Term. Amarin also will use Commercially Reasonable Efforts to Detail the Product and to optimize sales of the Product during the Term. The Parties
shall cooperate, including taking such actions as are reasonably requested by the other Party, in performing their obligations hereunder. 

4.2 Promotion Plan. Appropriate representatives from each Party will jointly prepare the initial Promotion Plan and provide it
to the JSC for review, comment, and approval prior to Kowa initiating its Promotion and Detailing activities hereunder. By no later than December 15 of the first Year, the JSC shall review, comment on (if applicable), and approve any
modifications to the initial Promotion Plan for the second Year of the Term, and shall thereafter update such Promotion Plan in accordance with Section 3.2(h) each Year thereafter that Kowa is Promoting and Detailing the Product. For clarity,
the Promotion Plan will include a plan for Detailing of the Product by the Kowa Sales Representatives and Amarin Sales Representatives to Targets that will permit the Parties to satisfy their minimum PDE obligations under Section 4.4.1(a) or
4.4.2(a), as applicable. 

  
 15 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 4.3 Sales Representatives. 

4.3.1 Generally. Kowa and Amarin shall at all times during the Term maintain a properly qualified and trained sales force
containing [***] of Sales Representatives in order to satisfy their respective obligations under this Agreement (including Kowa’s and Amarin’s express obligations under Section 4.4.1 and Section 4.4.2, respectively). 

4.3.2 Training. 

(a) Amarin shall be responsible for providing initial Product and sales training materials for all Kowa Sales Representatives and members of
Kowa’s sales management. In connection therewith, promptly after the Effective Date, Amarin will provide to Kowa sufficient copies of training materials and will make trainers reasonably available to train Kowa directly regarding compliance
related matters (including (A) Detailing in compliance with Applicable Laws, Product Labeling and applicable Kowa policies and (B) maintaining Samples and records related thereto in accordance the PDMA, other Applicable Laws, Product
Labeling and applicable Kowa policies) and to train Kowa trainers generally regarding the Product so that such Kowa trainers can train the Kowa Sales Representatives. Following Amarin’s initial direct training regarding compliance related
matters (which may be done together with Kowa trainers), Kowa trainers shall be responsible for the further training and retraining of Kowa Sales Representatives regarding such matters. Kowa’s trainers and Product marketers shall have the
right, with respect to the Product, to monitor and observe Amarin’s sales training programs and have ongoing access to new training materials developed by Amarin; provided, that (1) Amarin shall be entitled to exclude any person from such
training for competitive reasons or to protect its confidential information or trade secrets pertaining to matters other than the Product and (2) such monitoring or observation is not disruptive to the training. 

(b) Amarin’s training of Kowa personnel shall be conducted at places and times to be mutually agreed upon by the Parties promptly after
the Effective Date; provided, that such training shall be consistent with Amarin’s regularly scheduled training programs. Amarin shall provide such training using a training program that relates to the Product (including training materials) and
that is provided to Amarin’s sales force (with respect to Kowa Sales Representative level training and materials) or to Amarin’s district managers (with respect to Kowa’s sales management level training and materials). After the
initial training, Amarin shall periodically provide additional training and continuing education materials to Kowa and Kowa’s trainers (as applicable), at Kowa’s expense except for Amarin’s travel and personnel expenses, on a regular
basis so that Kowa may align on-going training of the Kowa Sales Representatives to the content training provided to Amarin Sales Representatives. Amarin agrees to provide such initial and additional training at Kowa’s cost, except for
Amarin’s travel and personnel expenses, consistent with and on a schedule no less frequent than that provided to Amarin Sales Representatives by Amarin. The Parties shall work in good faith to arrange a mutually satisfactory training schedule
for the Kowa Sales Representatives and Kowa’s sales management. 
 (c) No Kowa Sales Representative shall Promote or Detail the Product
without having undergone training. Amarin shall have the right to monitor or observe all such Kowa training and training materials. The Parties acknowledge and agree that in order for a Kowa Sales Representative to be deemed to have successfully
completed the training, such Kowa Sales Representative must demonstrate thorough knowledge of the medical and technical 

  
 16 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 
aspects of the Product and applicable commercial practices policies and must achieve scores on Product certifications of at least [***] percent ([***]%) on original testing or, if required, on
re-testing on Product certifications. Kowa covenants that it shall use only training materials provided by, or approved by, Amarin in the performance of its responsibilities under this Agreement, and such materials shall not then be modified,
changed, misbranded, or altered by Kowa or any Kowa Sales Representative at any time. 
 (d) Kowa shall bear all incremental costs and
expenses of the trainers (except for Amarin’s travel and personnel expenses), training facility and training materials to train the Kowa Sales Representatives and Kowa’s sales management, and Kowa shall be responsible for all travel
expenses and Out-of-Pocket Expenses incurred by the Kowa Sales Representatives and Kowa’s sales management in connection with such training. 

4.3.3 Incentive Bonus. During the Term, at least [***] percent ([***]%) of the annual sales incentive bonus payable to a Kowa
Sales Representative shall be allocated to the Product. The bonus shall not be capped. 
 4.3.4 Background Checks. Prior to
assignment to Promote or Detail the Product, Kowa shall be responsible for performing background checks of all Kowa Sales Representatives. Kowa warrants that it has completed a background check of all Kowa Sales Representatives to determine
(i) that no Kowa Sales Representative has any felony conviction and (ii) that no Kowa Sales Representative (A) is an excluded person on the OIG’s List of Excluded Individuals/Entities, (B) is on the General Services
Administration Excluded Parties List, or (C) is on the FDA Debarment List. 
 4.3.5 Performance. Kowa agrees with respect
to itself and the Kowa Sales Representatives that: 
 (a) Within five (5) Business Days after the Effective Date, Kowa will provide to
Amarin Kowa’s sales force, marketing, Sample and related compliance program standard operating procedures (SOPs) (“Sales Force SOPs”), including such procedures as Amarin may specifically identify, to enable Amarin to determine
whether such Sales Force SOPs are compliant with Applicable Laws and materially comparable to Amarin’s applicable standard operating procedures. Kowa will instruct the Kowa Sales Representatives to follow and comply with relevant portions of
the Sales Force SOPs on or prior to the Effective Date, as such policies may be updated from time to time by Kowa to be compliant with Applicable Laws, and promptly reviewed by Amarin prior to implementation. 

(b) Kowa will instruct the Kowa Sales Representatives to use, and will actively monitor and investigate (consistent with an effective
comprehensive compliance program required under Applicable Laws) the Kowa Sales Representatives to ensure that such Kowa Sales Representatives use, only Promotional Materials, Samples and literature approved for use by Amarin for the Promotion and
Detailing of the Product. Kowa will not, and will ensure that the Kowa Sales Representatives do not, misbrand, change or alter any Promotional Material or Samples (or use, sell or trade any Samples) supplied to it for distribution by Amarin; 

  
 17 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 (c) Kowa will instruct the Kowa Sales Representatives to do, and will
monitor the Kowa Sales Representatives so that such personnel do, the following: (A) Promote and Detail in full compliance with the Product Labeling and in adherence to all Applicable Laws, Sales Force SOPs, the Codes, and the Promotion Plan,
and (B) not Promote or Detail the Product using social media, emails, or the internet. 
 (d) Kowa will comply with all
Applicable Laws in the hiring, employment, and discharge of all Kowa Sales Representatives. Kowa represents that it is an Equal Opportunity Employer and does not discriminate against any person because of race, color, creed, age, sex, sexual
preference, marital status, or national origin. 
 (e) Kowa acknowledges and agrees that Amarin does not and will not maintain or procure
any worker’s compensation, healthcare, or other insurance for or on behalf of the Kowa Sales Representative, all of which shall be Kowa’s sole responsibility. 

(f) Kowa acknowledges and agrees that all Kowa Sales Representatives are employees of Kowa and are not, and are not intended to be or be
treated as, employees of Amarin or any of its Affiliates, and that such individuals are not, and are not intended to be, eligible to participate in any benefits programs or in any “employee benefit plans” (as such term is defined in
Section 3(3) of ERISA) that are sponsored by Amarin or any of its Affiliates or that are offered from time to time by Amarin or its Affiliates to their own employees (the “Benefit Plans”). 

(g) Notwithstanding Amarin’s rights to review, monitor or audit Kowa materials or activities, Kowa shall be solely responsible for its
acts and omissions and for those acts or omissions of the Kowa Sales Representatives while performing any activities under this Agreement. Kowa shall be solely responsible and liable for all probationary and termination actions taken by it, as well
as for the formulation, content and dissemination (including content) of all employment policies and rules (including written probationary and termination policies) applicable to its employees and contractors. 

4.3.6 Compensation. Kowa shall be solely responsible for all costs and expenses of recruiting, hiring, maintaining and
compensating the Kowa Sales Representatives, including salaries, benefits and incentive compensation; provided, that such incentive compensation shall be subject to Section 4.3.3 and shall not be structured in a manner that would reasonably be
expected to inappropriately motivate such individuals to engage in the improper Promotion or Detailing of the Product. Amarin shall not be responsible to Kowa, or to the Kowa Sales Representatives, for any compensation, expense reimbursements or
benefits (including vacation and holiday remuneration, healthcare coverage or insurance, life insurance, severance or termination of employment benefits, pension or profit-sharing benefits and disability benefits), payroll-related taxes or
withholdings, or any governmental charges or benefits (including unemployment and disability insurance contributions or benefits and workmen’s compensation contributions or benefits) that may be imposed upon or be related to the performance by
Kowa and such individuals of this Agreement, all of which shall be the sole responsibility of Kowa, even if it is subsequently determined by any court or governmental agency that any such individual may be an employee or a common law employee of
Amarin or any of its Affiliates or is otherwise entitled to such payments and benefits. 

  
 18 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 4.3.7 Product Basket Limitations. In connection with the
fulfillment of Kowa’s Annual PDE Requirements under this Agreement, a Kowa Sales Representative shall not [***]. 
 4.3.8
Transitioning Kowa Sales Representatives. If a Kowa Sales Representative leaves the employ of Kowa, or otherwise ceases to Detail the Product, Kowa shall, to the extent consistent with, and in a manner similar to, its practices with respect
to departures of sales representatives promoting, marketing or detailing other products for Kowa, account for, and shall cause such departing Kowa Sales Representative to return to Kowa and delete from his/her computer files (to the extent such
materials or information have been provided in, or converted into, electronic form), all materials relating to the Product that have been provided to such individual, including Samples (if applicable), Promotional Materials and account level
information and training program materials, including all copies of the foregoing. Kowa shall reuse such materials for replacement Kowa Sales Representatives, to the extent practicable. 

4.3.9 Kowa Sales Representative Audit. Amarin shall be entitled to audit Kowa’s training and compliance programs and the
performance of the Kowa Sales Representatives, including compliance with the Sales Force SOPs and including by way of accompanying the Kowa Sales Representatives during their performance of Promotion and Detailing hereunder, in accordance with
Section 7.5.5. 
 4.4 Minimum Sales Support. 

4.4.1 By Kowa. 

(a) Kowa shall provide the following minimum Details per [***] (“Annual PDE Requirements”) using no less than two hundred
fifty (250) Kowa Sales Representatives: 
  

			
	 [***]
	  	[***]
	 Primary Details
	  	[***]
	 Secondary Details
	  	[***]

 The [***] reference period for the performance of Kowa’s Annual PDE Requirements (a “Sales Year”) shall
commence as of the first full calendar month after the date that the first Detail of the Product in the Territory is performed by Kowa (following completion of training obligations described herein with respect to Kowa Sales Representatives
performing such Details) and reported in Kowa’s Detail recording system (such first Detail shall commence and constitute the “Product Launch”); provided, that Kowa’s Annual PDE Requirements shall be pro-rated for the final
Year of the Term on the basis of such Detailing obligations being allocated evenly over an entire Sales Year (e.g., if the final Year of the Term overlaps with only three (3) months of a Sales Year, then Kowa shall only be obligated to perform
one-fourth (1/4) of such Details). Kowa shall promptly advise Amarin in writing regarding any vacancies among the Kowa Sales Representatives that cause it to fall beneath the minimum Kowa Sales Representatives described above and shall, in any
event, fill any such vacancies with appropriately qualified persons within [***]. “Sales Quarter” means the three (3)-month period commencing with the first full calendar month after Product Launch and each consecutive three
(3)-month period thereafter. If Kowa fails to satisfy Kowa’s Annual PDE Requirements in a Sales Quarter, then[***]. 

  
 19 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 (b) In addition to its obligations under Section 4.4.1(a), Kowa
shall expend [***] during the [***] in Marketing Expenses (which amount, for clarity, is exclusive of Kowa’s sales force-related costs); provided, that if Net Sales of the Product in the Field in the Territory during [***] exceed [***], then
amounts that Kowa spent purchasing Samples during [***] shall reduce Kowa’s “Other Marketing Expenses” obligation under this Section 4.4.1(b) for [***] on a [***] to be pro-rated depending on the first day of Product Launch,
assuming an effective Sales Year of [***]. For clarity, [***]. Kowa shall expend the foregoing sums on a [***] as follows: 
  

																									
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 Sample Costs
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 Other Marketing Expenses
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 Sub-Total
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  

 If Kowa fails to expend the amount required with respect to [***], then Kowa shall [***]. In the event that Kowa has not [***]
and [***], Kowa shall [***]; provided, that, with respect to [***]. 
 4.4.2 By Amarin. 

(a) Amarin shall provide [***]; provided, that such Detailing obligations shall be [***] on the basis of such Detailing obligations being
[***]. If Amarin fails to satisfy Amarin’s Annual PDE Requirements in any Sales Quarter then[***]. 
 (b) In addition to its
obligations under Section 4.4.2(a), Amarin shall [***] during the Initial Term in Marketing Expenses [***]. 
  

																									
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 Sample Costs
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 Other Marketing Expenses
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 Sub-Total
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  

 If Amarin fails to expend the amount required with respect to [***], then Amarin shall [***]. 

  
 20 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 4.5 Records and Reports. 

4.5.1 Record Keeping. Commencing the month in which Product Launch occurs, Kowa shall record, [***]: (i) the number of Kowa
Sales Representatives assigned to Detail the Product in the Territory, (ii) the territories of their assignments, (iii) the proportion of their time devoted to Promoting the Product, (iv) the number of Product-related Details and PDEs
for Product made by Kowa Sales Representatives in the Territory, (v) the position of such Details, (v) the amount of Marketing Expenses incurred, (vi) the amount of Samples dispensed to each physician Target, (vii) the prescriber
identity (including applicable NPI number) of those receiving Samples, (viii) data required for government, state and other regulatory reporting requirements (including, data required under Section 1128G of the United States Social
Security Act (i.e., the Physician Payment Sunshine Law) such as food, drops of literature, any gifts, payments or other transfers of value, state law data such as total spends in Minnesota, Massachusetts and California, and total marketing costs
expended in Washington and West Virginia), and (ix) such other information as the JSC may reasonably require and as may be required by Applicable Laws (collectively, the “Promotional Activity Data”). 

4.5.2 Reporting by Kowa. In addition to the record keeping requirement set forth in Section 4.5.1, within [***] after the
end of each [***] commencing with the [***] in which Product Launch occurs, Kowa shall furnish to Amarin a written report setting forth Kowa ’s Promotional Activity Data for such month. In addition, within [***] after the end of each Year
commencing with Year 2014, Kowa shall furnish to Amarin a written report setting forth, in the aggregate, the number of Kowa Sales Representatives assigned to the Product in the Territory, the number of PDEs for the Product provided by Kowa in the
Territory during such Year, and the total Marketing Expenses incurred. Unless otherwise agreed by the JSC, Kowa’s reporting and record keeping with respect to Promotional Activity Data, including the calculation of Details and PDEs shall be in
a format in reasonably acceptable to Amarin. 
 4.5.3 Reporting by Amarin. Within [***] after the end of each [***] commencing
with the [***] in which Product Launch occurs, Amarin shall furnish to Kowa a written report setting forth the number of Product-related Details and the PDEs for Product made by Amarin Sales Representatives in the Territory for such [***]. 

4.6 Promotional Materials. 

4.6.1 Generally. Amarin shall provide Kowa with all Promotional Materials to be used by the Kowa Sales Representatives in
performing Promotion and Detailing activities under this Agreement. Kowa covenants that it shall use only Promotional Materials provided by Amarin in the performance of its responsibilities under this Agreement, and such materials shall not be
modified, changed, misbranded, or altered by Kowa or any Kowa Sales Representative at any time, and Kowa and its Kowa Sales Representatives shall not use any Product Labeling that was not supplied by Amarin. Amarin shall create and control any
digital marketing materials and Kowa shall not Promote or Detail the Product using social media, email or the internet. Kowa shall be timely provided such quantity of Promotional Materials as is set forth in the Promotion Plan or as may be
determined by the JSC from time-to-time, which shall be reasonably sufficient to enable Kowa to meet its objectives under this Agreement. The Promotional Materials shall be in compliance in all material respects with the Product Labeling approved by
the FDA and all Applicable Laws in the Territory and shall be suitable for use for Promotion of the Product in the Field. 

  
 21 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 4.6.2 Costs. Notwithstanding anything to the contrary
herein, Kowa shall be responsible for any incremental costs (including Out-of-Pocket Expenses, but excluding personnel costs) that Amarin incurs in providing Kowa with Promotional Materials or any other items or services hereunder. “Incremental
costs” under this Section 4.6.2 is understood to be [***]. Amarin shall invoice Kowa for such costs from time-to-time, which invoices Kowa shall pay within thirty (30) days of receipt. 

4.7 Performance Standards. Each Party will ensure the overall quality of Product Promotional efforts being provided by its Sales
Representatives in the Territory, such quality being based on measures of compliance audit results (including those conducted pursuant to Section 7.5.5), call activity, message delivery and consistency, attendance at training seminars and
Product meetings, proficiency with Product (including as set forth in Section 4.3.1), and other measures of performance (collectively, “Performance Standards”) established by the JSC and communicated to the Parties, including
through the Parties’ representatives on the JSC. The JSC shall review the Performance Standards on an annual basis and update the Performance Standards if and when necessary based on evolving measurement tools, market conditions, commercial
strategy and/or other relevant factors. 
 4.8 Samples. 

4.8.1 Samples Generally. Amarin shall supply the quantity of Samples specified in the Promotion Plan to Kowa or Kowa’s
designee in accordance with ARTICLE 6. Amarin shall be responsible for the design, production and procurement of all aspects of all Samples. 

4.8.2 Sample Accountability Policies and Procedures. 

(a) Kowa shall, and shall ensure that Kowa Sales Representatives, store, handle, transport and distribute Samples, and conduct Details, in
accordance with the conditions set forth in the Product Labeling, the Sales Force SOPs, Kowa’s other applicable standard operating procedures, and otherwise in accordance with the PDMA and all other Applicable Laws governing the storage and
distribution of pharmaceutical samples, and shall employ such measures as are necessary (including compliance with any Product insert) to prevent Sample contamination, deterioration or adulteration. 

(b) Kowa will not distribute Samples to any Kowa Sales Representative that has not been trained in accordance with the Sales Force SOPs. From
and after receipt by Kowa, Kowa’s distribution facilities and Kowa Sales Representatives shall (A) secure Samples against theft, tampering and diversion during and after storage and transport and (B) store Samples in a proper
environment in accordance with the Product Labeling and any instructions received from Amarin with respect thereto. 
 (c) Amarin may, upon
reasonable notice to Kowa, review Kowa’s sample accountability program for the Product. Amarin may choose to utilize the services of an outside vendor to perform this review. 

  
 22 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 (d) Kowa will validate, or cause to be validated, the licensing
status/sample eligibility of the prescribers selected to receive Samples and will maintain, or cause to be maintained, an up to date status file thereafter. Amarin shall be entitled to periodically conduct, or have conducted, an audit of Kowa’s
license/sample eligibility status file for the Product to ensure that Kowa is properly validating such prescribers. Such status file shall be validated not less than (A) once per Year and (B) periodically throughout the Year when new
Targets are added to the list of Targets eligible to receive Samples. 
 (e) Kowa covenants and warrants that it and the Kowa Sales
Representatives shall: (A) only use Samples directly in connection, and accordance, with the PDMA and other Applicable Laws, and this Agreement and (B) not resell, repackage, trade, use deconstruct, reverse engineer or otherwise use
Samples or their packaging in any other non-compliant manner. 
 4.8.3 Certain Issues Involving Samples. Kowa shall notify
Amarin within one (1) Business Day after receipt of information suggesting that (i) any Sample has been lost or stolen, (ii) any person has falsified a Sample request, a Sample receipt or Sample records, (iii) any Person is
diverting Samples, (iv) any Samples have otherwise not been handled in accordance with the terms of this Agreement or Applicable Laws, or (v) any Sample is defective. Kowa and Amarin shall cooperate in making such investigations and
reports related thereto as may be necessary under Applicable Laws. Kowa shall make drug accountability reports, Sample requests and receipts, and any other records pertaining to Samples or matters subject to PDMA, available to Amarin within
twenty-four (24) hours of Amarin’s request. Kowa shall keep full and accurate books and records with respect to all of its obligations under the PDMA and Amarin shall have the right to audit such books and records in accordance with
ARTICLE 8. 
 4.9 No Sales or Distribution; Returns. With respect to the Territory, Amarin shall sell (whether directly
or through a designee) all Product to each customer, and shall book each sale. The Parties recognize that Kowa may from time to time receive orders for the Product directly from Third Parties for delivery in the Territory. In such event, Kowa
promptly shall advise such Third Party that Kowa is not authorized to accept orders for the Product and shall immediately and accurately forward such order to Amarin, or its designee, which order Amarin may accept or reject in its sole discretion.
Amarin (whether directly or through a designee) shall be responsible for handling all returns of the Product with respect to the Territory. If any Product sold in the Territory is returned to Kowa, Kowa shall either instruct the returning Party to,
or shall itself if providing such instructions in a timely manner is not feasible (e.g., if Kowa receives a return through the mail), return such Product with appropriate documentation directly to Amarin or its designee, as directed by Amarin, at
Amarin’s expense and in accordance with all Applicable Laws, as amended by the Drug Quality and Security Act (DQSA), but shall take no other actions with respect to such return without the prior written consent of Amarin. Amarin shall (whether
directly or through a designee) have sole responsibility for shipping, distribution and warehousing, for the invoicing and billing of purchasers of the Product and for the collection of receivables resulting from the sales of the Product in the
Territory. 
 4.10 Managed Care Organizations. Amarin will have sole responsibility for Promoting to, contracting with,
and undertaking any and all other interactions regarding the Product with, managed health care organizations, group purchasing organizations, pharmacy benefit managers, large employers, long-term care organizations, insurers, formularies, government
agencies and programs (e.g., Medicare and the Veterans Health Administration and other federal, state and local agencies), or similar organizations. 

  
 23 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 4.11 Joint Activities. From time to time during the Term,
the Parties may agree to permit joint promotional activities including both Kowa Sales Representatives and Amarin Sales Representatives, and the Parties will [***]. 

4.12 Communication with Sales Representatives. Each Party shall only communicate with designated representatives of the other
Party (including, for example, through members of the JSC and designated subcommittees). Notwithstanding the foregoing, nothing herein shall restrict the Kowa Sales Representatives and Amarin Sales Representatives from communicating directly with
one another. For clarity, as noted in Section 1.53, Kowa Sales Representatives shall not include MSLs; provided, however, that Amarin may provide information with respect to the Product to MSLs of Kowa for purposes of informing such MSLs about
the Product in connection with such MSLs presence at relevant conferences. 
 4.13 Prohibition on Solicitation. Without
the prior written consent of the other Party, neither Party nor its Affiliates shall, during the Term and for the longer of (i) a period of [***] following the expiration or termination of this Agreement or (ii) the duration of any Tail
Period, solicit (directly), or attempt to solicit, any employee, director, or consultant who was employed or engaged by the other Party or its Affiliates. This provision shall not restrict either Party or its Affiliates from advertising employment
opportunities in any manner that does not directly target employees, directors, or consultants of the other Party or its Affiliates or from employing anyone who responds to such advertisements. 

ARTICLE 5 
 FINANCIAL
PROVISIONS 
 5.1 Consideration Generally. In consideration for the performance of Kowa’s obligations hereunder,
including compensation for Kowa’s Detailing efforts hereunder, during the Term Amarin shall pay Kowa a Quarterly percentage of the Gross Margin for the Product in the Territory (the “Co-Promote Fee”). In addition, following the
expiration or earlier termination of the Term, under certain circumstances, Amarin shall pay to Kowa the Tail Period Payments, all as detailed herein. 

5.2 Co-Promote Fee. The percentage used to calculate the Co-Promote Fee shall vary from Year-to-Year in accordance with
Schedule 5.2. For clarity, in calculating Net Sales and Gross Sales for purposes of determining Gross Margin and the Co-Promote Fee the following principles shall apply: [***] 

5.3 Tail Period Payments. 

5.3.1 Upon Expiration. In the event that this Agreement expires in accordance with Section 12.1, and subject to
Section 2.2, then Amarin shall pay Kowa the following “Co-Promote Fee Tail Payment” in accordance with Section 13.5(a): [***] 

  
 24 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 5.3.2 Upon Certain Terminations. In the event that this
Agreement is terminated prior to the expiration of the Term under the circumstances described in this Section 5.3.2 then Amarin shall pay Kowa the indicated “Net Sales Tail Payment” for the relevant indicated period in
accordance with Section 13.5(b): 
 (a) if such termination occurs pursuant to Section 12.4.1 in connection with a Change of
Control of Amarin (regardless whether such termination is initiated by Amarin, Amarin’s successor or Kowa) and on or prior to the second anniversary of the Effective Date, and subject to Section 2.2: [***] 

(b) if such termination occurs pursuant to (1) Section 12.4.1 in connection with a Change of Control of Amarin (regardless whether
such termination is initiated by Amarin, Amarin’s successor or Kowa) and following the [***] of the Effective Date, or (2) Section 12.4.1 in connection with a Change of Control of Kowa and such termination is initiated by Amarin
(regardless whether such termination occurs prior to, on or after the [***] of the Effective Date), or (3) Section 12.3(a) in connection with a material breach by Amarin and is initiated by Kowa (regardless whether such termination occurs
prior to, on or after the [***] of the Effective Date), and, in all cases of clauses (1), (2) and (3), subject to Section 2.2: [***] 

(c) if such termination occurs pursuant to Section 12.2 in accordance with the Parties’ mutual agreement (which termination, for
clarity, may not be effective prior to the [***] of the Effective Date), and subject to Section 2.2: 
 (i) if such mutual termination
occurs in connection with a Major Market Event: [***] 
 (ii) if such mutual termination occurs between the [***] of the Effective Date
(and is not in connection with a Major Market Event): [***] 
 (iii) if such mutual termination occurs between the [***] of the Effective
Date (and is not in connection with a Major Market Event): [***] 
 (iv) if such mutual termination occurs between the [***] of the
Effective Date (and is not in connection with a Major Market Event): [***] 
 5.3.3 Tail Period Payments Generally. Kowa shall be
entitled to receive the Tail Period Payments solely under the circumstances described in Sections 5.3.1 and 5.3.2 and as further described in Section 13.5. For clarity, but without limitation, if this Agreement is terminated prior to expiry of
the Term by (i) Amarin due to a material breach by Kowa or in accordance with Sections 4.4.1(a) and/or 12.6, (ii) Kowa, or its successor, in connection with a Change of Control of Kowa in accordance with Section 12.4.1, or in
connection with a waiver in accordance with Section 2.2.2(ii), or in accordance with Sections 4.4.2(a) and/or 12.7, or (iii) either Party for any reason other than those expressly described in Section 5.3.1 or Section 5.3.2 then,
in each case of the foregoing clauses (i) through (iii), inclusive, Kowa shall not be entitled to receive, and Amarin shall not be obligated to pay Kowa, any Tail Period Payments. 

  
 25 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 5.4 Reporting and Payment. 

5.4.1 Quarterly Reports, Invoicing and Co-Promotion Fee Payments. [***] Amarin shall deliver to Kowa a written report setting
forth its calculations of Gross Margins and the Co-Promote Fee due to Kowa in connection with such Gross Margins for the just-ended Quarter. 

5.4.2 Payments. All payments under this Agreement shall be in Dollars in immediately available funds. Unless instructed
otherwise by the receiving Party, payments shall be made via wire transfer to an account designated in writing from time to time by the receiving Party. 

5.5 Taxes. Any withholding or other similar taxes that either Amarin or its Affiliates is required by Applicable Law to withhold
or pay on behalf of Kowa, with respect to any payments to it hereunder, shall be deducted from such payments and paid contemporaneously with the remittance to Kowa; provided, however, that Amarin will furnish Kowa with proper evidence of the taxes
so paid. Kowa will furnish Amarin with appropriate documents to secure application of the most favorable rate of withholding tax under Applicable Law. All sums due under this Agreement shall be paid without deduction of sales tax that may be
imposed, except insofar as Amarin is required to withhold or deduct the same to comply with Applicable Laws. Each Party shall render the other reasonable assistance in respect of its efforts to apply for and receive any refunds of tax to which it
may seek. 
 5.6 Costs Generally. [***] 

5.7 Offset Rights. Notwithstanding anything to the contrary in this Agreement, either Party may, in its sole discretion and from
time to time, offset against any payments due to the other Party or its Affiliates under this Agreement, any amount that the other Party owes or has failed to pay in accordance with the applicable terms of this Agreement. 

ARTICLE 6 
 SUPPLY OF
SAMPLES 
 6.1 Sample Ordering and Delivery. Amarin will ship Sample supplies in quantities, and on timing, set forth in
the Promotion Plan. Amarin will ship (FCA (Incoterms 2010) – Amarin’s or its contract manufacturer’s facility) Samples to Kowa’s warehouse located at 530 Industrial Park Blvd, Montgomery, AL 36117. Kowa shall confirm in writing
the receipt of all Samples within one (1) Business Day of any such delivery of Samples and in compliance with Applicable Laws. Kowa may not change the location of the warehouse to where the Samples are shipped without the prior written consent
of Amarin. Shipping costs from Kowa’s warehouse to Kowa Sales Representatives or Targets will be at Kowa’s cost and responsibility. 

6.2 Receipt and Inspection. 

6.2.1 Inspection. Kowa will perform an initial visual inspection (which shall at least be in accordance with PDMA and
Kowa’s standard operating procedures) of each shipment of Samples immediately upon receipt of a shipment and communicate shortages, damages or 

  
 26 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 
other issues to Amarin or its designee via phone call and confirmed in writing. Thereafter, Kowa shall comply with the PDMA and other Applicable Laws. If any Samples are damaged, shorted or
misbranded, Kowa will promptly notify Amarin. Kowa will return any non-conforming Samples in accordance with Amarin’s direction at Amarin’s cost. Amarin will replace the non-conforming Samples at Amarin’s expense and shall supply such
Samples to Kowa under conditions no less favorable than Amarin’s then-current supply of Samples to Amarin Sales Representatives. Kowa’s sole remedy with respect to any damaged, misbranded or shorted Samples shall be the replacement of such
Samples by Amarin. 
 6.2.2 Records. Amarin will maintain records of all Sample shipments and quantities sent to and received
by Kowa or its designee. Kowa will maintain Sample shipment records of each Kowa Sales Representative by employee ID and territory number for the current Year plus the three (3) most recent previous Years. The information maintained must
include the following: (i) product code, name and strength, (ii) lot number and quantity shipped, and (iii) shipment date. For clarity, Amarin will not ship Samples directly to Kowa Sales Representatives. 

6.2.3 Storage & Reporting. Kowa represents and warrants that it and the Kowa Sales Representatives have a secure and
proper environment for storage of Samples in accordance with the Product Labeling. Kowa agrees to provide monthly reporting of Sample stock levels to Amarin in a mutually agreed upon format. 

6.3 Sample Cost. Samples supplied to Kowa under this Agreement will be supplied by Amarin [***]. Amarin will provide
invoices to Kowa that are consistent with the definition of Sample Cost and the quantities of Samples shipped under such invoice. Sample-related invoices will be paid by Kowa within [***] of receipt thereof. 

ARTICLE 7 
 REGULATORY
MATTERS, COMPLIANCE AND PHARMACOVIGILANCE 
 7.1 Responsibility. Amarin shall generally have responsibility for all
regulatory matters associated with the sales of the Product except that Kowa is responsible for (a) obtaining all federal, state or local licenses or credentialing necessary for Kowa Sales Representatives to Detail the Product in the Territory,
(b) federal, state and local aggregate spend filings in respect of its activities, except for filings in District of Columbia, West Virginia, and Massachusetts, (c) any issues related to PDMA sample accounting/auditing, thefts or losses
with respect to Samples supplied by Amarin to Kowa hereunder, and (d) notwithstanding the foregoing, compliance with Applicable Laws. Kowa will provide a copy of all correspondence and/or PDMA audit results to Amarin within two (2) days of
completion thereof. Amarin’s responsibilities shall specifically include all communications with the FDA related to the Product and Amarin shall have sole responsibility to seek and/or obtain any necessary approvals of the Product Labeling used
in connection with the Product in the Territory, and for determining whether the same requires approval. 

  
 27 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 7.2 Reporting. Amarin shall be responsible for any
reporting of matters, or other communications regarding manufacture, medical/scientific, sale, or promotion of the Product, including Adverse Events, to or with the FDA and other relevant regulatory authorities, in accordance with Applicable Laws.
Without limiting the foregoing, Kowa shall promptly, but in any event within one (1) Business Day, notify Amarin of any information that it receives regarding an Adverse Event, suspect, counterfeit, misbranded or illegitimate Product, or
otherwise obtains that may require a recall, field alert, notice to FDA or other Regulatory Authority, Product withdrawal or field correction arising from any defect in the Product or that may have an impact on Regulatory Approval for the Product or
the continued commercialization of the Product or Product sampling. 
 7.3 Kowa Involvement. Subject to
Section 7.1 herein or a specific requirement of Applicable Law, Kowa shall provide a copy of, and obtain Amarin’s written consent prior to communicating or corresponding with the FDA or with any other Governmental Authority, concerning the
Product, or otherwise take any action concerning any authorization or permission under which the Product is sold. Kowa shall provide to Amarin, upon receipt, copies of any communication from the FDA or other Governmental Authority related to the
Product. If Kowa has a good faith belief that it is legally obligated to communicate with the FDA or other Governmental Authority, then Kowa shall promptly so advise Amarin and Kowa shall, if Applicable Law permits, comply with any and all
reasonable direction from Amarin concerning any meeting or communication with the FDA or other Governmental Authority; provided, that, Amarin shall, unless prohibited by Applicable Law, have the right to participate in any meetings or other
communications between Kowa and any Governmental Authority with respect to the Product. 
 7.4 Regulatory Inspection or
Audit. The Parties agree that they will conduct all audits required under PDMA and, additionally, if a Regulatory Authority desires to conduct an inspection or audit of either Party’s facility or a facility under contract with either
Party with regard to the Product in the Field in the Territory, such Party shall cooperate and cause the contract facility to cooperate with such Regulatory Authority during such inspection or audit. Following receipt of the inspection or audit
observations of such Regulatory Authority (a copy of which such Party will promptly provide to the other Party), such Party will prepare the response to any such observations. Such Party agrees to conform its activities under this Agreement to any
commitments made in such a response, except to the extent it believes in good faith that such commitments violate Applicable Laws. 

7.5 Compliance. 

7.5.1 General Compliance Obligations. During the Term, the Parties, through a compliance subcommittee under the JSC, shall
consult on all medical and regulatory compliance matters solely as it relates to the Product, including any reports as to their compliance with the Act, the Physicians Payment Sunshine Act, PDMA, HIPAA, the Codes and OIG Guidance. The Parties agree
to work jointly in good faith to ensure that their internal policies are consistent with Applicable Law and, to the extent desirable, each other’s policies. In performing its duties hereunder, Amarin and Kowa shall and shall cause its
respective Sales Representatives to: (i) Promote the Product in conformity with its FDA approved Product Labeling, and (ii) comply with all Applicable Laws, including all regulations and other guidelines concerning the advertising of
prescription drug products, the OIG Guidance, the Codes, the Accreditation Council for Continuing Medical Education standards, and its standard operating procedures, in 

  
 28 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 
each case, to the extent applicable to the activities to be performed hereunder and as may be amended or supplemented from time to time. Kowa and Amarin shall each use Commercially Reasonable
Efforts to ensure that each of its employees, agents and consultants do not make any representation, statement, warranty or guaranty with respect to the Product (1) that is inconsistent with its current FDA approved Product Labeling or with the
Promotional Materials, (2) that is deceptive or misleading, (3) that misbrands or adulterates the Products, or (4) that disparages the Product or the good name, goodwill or reputation of Amarin, Kowa or their respective Affiliates.
Each Party shall use Commercially Reasonable Efforts to ensure that its activities under this Agreement will be provided in a professional, ethical and competent manner. Unless otherwise required by Applicable Law, Kowa and Amarin shall each
maintain sole responsibility for its compliance with Applicable Law regarding Promotion and Detailing of prescription drug products, including the maintenance of an effective comprehensive compliance programs and the reporting of respective sales
force activities. 
 7.5.2 OIG Guidance. Consistent with the ‘Compliance Program Guidance for Pharmaceutical
Manufacturers,’ published by the Office of Inspector General, United States Department of Health and Human Services (the “OIG Guidance”), each Party agrees to maintain an effective compliance program with respect to its
Promotion and Detailing activities pursuant to this Agreement containing all of the elements described in such guidance document. 

7.5.3 Compliance Reporting Obligations. 

(a) Each Party shall maintain an effective comprehensive corporate compliance program (including an investigation system that is compliant
with Applicable Laws) that will include a mechanism for its employees to report, anonymously if they choose, any concerns about potential illegal activity relating to Promotion of Product in the Territory, and that will require a Party to
investigate any such report. Kowa shall give written notice to Amarin of the substance of any such report within a reasonable time (but in no event later than five (5) Business Days) after such report is received, and before reporting any such
activity to any Regulatory Authority or law enforcement authority. Kowa shall inform Amarin of the result of any investigation of such report (unless the reporting Party concludes in good faith that doing so would violate Applicable Laws) within
five (5) Business Days after learning of such result, and cooperate in good faith with Amarin on all reasonably requested corrective actions necessary under Kowa’s standard operating procedures or relevant practices and activities. 

(b) If a Party receives any written or oral communication from any Governmental Authority relating to its activities hereunder, then such
Party shall as soon as reasonably practicable (but in any event within twenty-four (24) hours) notify the other Party and provide such other Party with a copy of any written communication received by the first Party or, if applicable, complete
and accurate minutes of such oral communication. Each Party shall keep the other Party reasonably informed, including by way of promptly providing updates upon such Party’s request, with respect to the status and resolution of any issues raised
by any Governmental Authority relating to such Party activities hereunder. To the extent not prohibited by Applicable Law, Kowa shall reasonably consider and implement any guidance provided by Amarin with respect to such issues and interactions with
Governmental Authorities. 

  
 29 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 (c) Without limiting the foregoing, each Party’s comprehensive
corporate compliance program shall also include, and each Party shall carry out, a broad training program in ethics and compliance with Applicable Laws, such Party’s standard operating procedures and the Codes, in addition to the training
provided for in this Agreement. 
 7.5.4 Compliance Safe Harbor. Notwithstanding anything to contrary in this Agreement,
neither Party shall be required to undertake any obligation, or incur any cost or reimbursement obligation, in connection with any activity under this Agreement that it believes, in good faith, is not compliant with any Applicable Law. 

7.5.5 Compliance Audit. Without limiting the records-specific audit rights described in ARTICLE 8, during the Term and for six
(6) years thereafter, each Party shall, for the purpose of auditing and monitoring the performance of its compliance with this Agreement and particularly its compliance obligations hereunder, permit the other Party, its Affiliates, and any
auditors of any of them to have, upon reasonable notice, access to any premises of such Party or its Affiliates used in connection with this Agreement (“Audit”). To the extent that any Audit by a Party requires access and review of
any commercially or strategically sensitive information of the other Party or its Affiliates relating to the business of such Party or Affiliate, such activity shall be carried out by a Third Party professional advisor appointed by the other Party
and such professional advisors shall only report back to the other Party such information as is directly relevant to informing the other Party on such Party’s compliance with the particular provisions of the Agreement being Audited (and shall
enter into a commercially reasonable confidentiality agreement consistent with the foregoing). The costs and fees of any Audit shall be paid by the auditing Party, except that if an Audit reveals any material breach or violation by the audited Party
(including through any Affiliate) of any representation, warranty or undertaking set forth in Sections 4.3.2, 4.3.5, 4.8.2, 7.5, 11.1(e), 11.1(i) and 11.1(j), the costs of such inspection or Audit shall be paid by the Audited Party. The Audited
Party shall bear its own costs of rendering reasonable assistance to the Audit. 
 7.5.6 Compliance Certification.
Within thirty (30) days of each anniversary of the Effective Date, Kowa shall submit to Amarin a written certification by an appropriate corporate officer of Kowa, in a form reasonably acceptable to Amarin, regarding Kowa’s (and its Kowa
Sales Representatives, as applicable) compliance with the terms of Sections 4.3.2, 4.3.5, 4.8.2, 7.5, 11.1(e), 11.1(i) and 11.1(j) (i.e., certain of those provisions dealing with compliance-related matters). 

7.6 Pharmacovigilance. 

7.6.1 Generally. Amarin shall be responsible for all pharmacovigilance activities regarding the Product, including product
complaints, signal detection, medical surveillance, risk management, global medical literature review and monitoring, Adverse Event reporting and responses to Regulatory Authority requests or enquiries; provided, that, in the event Kowa receives
(i) Safety Information regarding the Product, or information regarding any safety-related regulatory request or inquiry, Kowa shall notify Amarin as soon as practicable, but, in any event, not later than one (1) Business Day after it
receives such Safety Information, Regulatory Authority request or query, or (ii) reports of any Adverse Events, such Adverse Event reports shall be immediately (but in any event within one (1) Business Day called-in to Amarin at
(855) 827-2372 (i.e., 855-VASCEPA). 

  
 30 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 7.6.2 Assistance. Each Party shall provide the other Party
with such information as the other Party may reasonably request during the Term in order to support the requesting Party’s compliance with Applicable Laws and its Sales Representatives Promotion and Detailing of the Product in the Field in the
Territory. Kowa shall report to Amarin, in accordance with commercially reasonable methodologies requested by Amarin, all information necessary to permit Amarin to make timely reports as required by any Regulatory Authority in the Territory
regarding the Product, and shall advise Amarin if there is any respect in which it has been unable to do so. To facilitate efficient communication and data sharing between Amarin and Kowa, Amarin shall establish and maintain a secure method of
transferring information between the Parties. The Parties shall work together to identify any support hardware, software and services appropriate for the sharing of information with respect to Promotion of the Product. Wherever possible, the Parties
agree that all technologies and platforms used for such purposes shall be in accordance with each Party’s technology architecture and security standards. Except as provided in this Agreement, each Party shall be solely responsible for all costs
and expenses of acquiring and maintaining its infrastructure and reporting systems to support its Sales Representatives. 
 7.6.3
Separate Agreement. Contemporaneous with the Effective Date, the Parties shall enter into a separate safety data exchange / pharmacovigilance agreement containing the specific terms, conditions and obligations of the Parties with respect to
the collection, reporting and monitoring of adverse drug reactions, Adverse Events, Product complaints, other relevant drug safety matters, and medical inquires with respect to the Product during the Term. 

7.7 Medical Inquiries. Amarin shall respond to all unsolicited requests for medical information. Promptly after the Effective
Date, the Parties shall establish procedures in accordance with the applicable portions of Amarin’s processes and procedures, to enable Kowa to send such requests to Amarin or its designee to enable prompt response to any medical inquiries.

 7.8 Recalls and Market Withdrawals. Amarin shall have the sole right and responsibility, at its expense (but subject to
Section 11.5), to control any product quarantine, recall, field correction, or withdrawal of the Product in the Territory. To the extent practicable, the Parties shall discuss the circumstances of any potential product quarantine, recall, field
correction or withdrawal of any Product and possible appropriate courses of action. Each Party shall maintain complete and accurate records of any recall in its territory for such periods as may be required by Applicable Laws, but in no event for
less than five (5) years.  
 7.9 Reporting Responsibilities. Each Party shall be responsible for its
federal and state reporting requirements in the Territory arising from conducting Details or related activity(ies) in the Territory or in a given state, as applicable; provided, that, with respect to state level reporting, Kowa shall not be
responsible for direct state reporting in those states where relevant reports are required to be submitted by the Regulatory Approval holder for the relevant product, in which states Kowa shall promptly (but no later than five (5) Business Days
before any such reporting deadline) provide Amarin any and all assistance and information that Amarin requires or reasonably requests to enable Amarin (or its designee) to submit such reports with respect to the Product and activities hereunder.

  
 31 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 7.10 Rebate Liability. Notwithstanding Kowa’s
reporting obligations under Section 7.2, Amarin agrees and acknowledges that it shall be solely responsible for any and all rebate, chargeback or adjustment amounts or liabilities owed by any party in connection with any sale or disposition of
the Product in the Territory, under applicable rules and regulations relating to the United States Medicaid Drug Rebate Program (42 U.S.C. § 1396r-8) and any state supplemental rebate program, Medicare average sales price reporting (42 U.S.C.
§ 1395w-3a), the United States Public Health Service Act (42 U.S.C. § 256b), the United States VA Federal Supply Schedule (38 U.S.C. § 8126) or under any state pharmaceutical assistance program or United States Department of Veterans
Affairs agreement, and any successor government programs. Notwithstanding anything to the contrary herein, all amounts associated with any rebate, chargeback or adjustment amounts or liabilities owed by any party in connection with any sale or
disposition of the Product in the Territory shall be included in the deductions from Gross Sales in calculating Net Sales. 

ARTICLE 8 
 AUDIT RIGHTS

 Without limiting any other express audit rights granted herein, each Party shall have the right, upon reasonable written notice
during the Term, and for [***] after expiration or termination of this Agreement, at such Party’s expense, through an independent certified public accountant reasonably acceptable to the other Party and upon execution of a confidentiality
agreement, to examine the records (including records relating to the Product, Sales Representatives, Detailing of the Product and other Promotional Activity Data, and sampling and related records) that such other Party is required to keep in
accordance with the terms of this Agreement during regular business hours; provided, however, that (i) such examination shall not take place more often than once per Year, (ii) such examination shall not cover records that have previously
been audited, and (iii) such accountant shall report to such Party only as to the accuracy of the reports or payments provided or made by the other Party under this Agreement. Any undisputed adjustments required as a result of overpayments or
underpayments identified through a Party’s exercise of audit rights shall be made by subtracting or adding, as appropriate, amounts from or to the next payment or, if no further payments are due, by payment to the Party owed such adjustment
within [***] days after identification of such adjustment. The Party requesting the audit shall bear the full cost of the audit; provided, however, the audited Party shall reimburse the requesting Party for such fees and expenses in the event the
audit reveals an error of overstatement or understatement equal to or exceeding [***] in the numbers reported in any Year. 

  
 32 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 ARTICLE 9 

INTELLECTUAL PROPERTY 

9.1 Ownership of Intellectual Property. Each Party shall have and retain sole and exclusive right, title and interest in and to
all inventions, discoveries, writings, trade secrets, know-how, methods, practices, procedures, engineering information, designs, devices, improvements, manufacturing information and other technology, whether or not patentable or copyrightable, and
any patent applications, patents, or copyrights based thereon (“Inventions”) that are made, discovered, conceived, reduced to practice or generated by such Party (or its employees or representatives) related to such Party’s
products (including, in the case of Amarin Ireland, the Product) during the Term and as a result of performance of this Agreement. Notwithstanding anything to the contrary herein, Amarin Ireland shall solely own all right, title and interest in and
to all Inventions relating to the Product, the active ingredients in the Product, and the uses thereof first made, discovered, conceived, reduced to practice or generated during the Term and as a result of performance of this Agreement by Amarin
Pharma (or its employees or representatives) or Kowa (or its employees or representatives) or Amarin Pharma (or its employees or representatives) and Kowa (or its employees or representatives) working together jointly (each, a “Product
Invention”). Kowa and Amarin Pharma each agrees to assign, and hereby does assign, to Amarin Ireland any and all right, title and interest Kowa or Amarin Pharma, as applicable, may have in or to any Product Invention. Kowa shall not
represent to any Third Party that it has any proprietary or property right or interest in the Product, or in any patent relating thereto, or in any trademark (other than Kowa Trademarks) used in connection therewith. For clarity, and notwithstanding
anything to the contrary contained herein, any and all Product Inventions and any information contained therein or related thereto shall constitute Confidential Information of Amarin. 

9.2 Prosecution, Maintenance, Enforcement and Defense of Amarin Intellectual Property. Amarin shall use Commercially Reasonable
Efforts to prosecute and maintain the Amarin Intellectual Property in the Territory, and Amarin shall have the sole right to enforce and defend Amarin Intellectual Property, and to settle or otherwise resolve related litigation, at Amarin’s
sole discretion. Without limiting the foregoing, Kowa shall provide assistance reasonably requested by Amarin, at the reasonable and pre-approved cost and expense of Amarin. Kowa shall neither be require to provide assistance for which Amarin has
not pre-approved the cost, nor shall Kowa’s reasonable assistance include an obligation on the part of Kowa to be named a party plaintiff in any claim or cause of action. In connection with the enforcement or defense of the Amarin Intellectual
Property (e.g., Amarin’s suit against Omthera Pharmaceuticals, Inc., a Delaware corporation, and its parent company, AstraZeneca Pharmaceuticals LP, seeking injunctive relief and monetary damages for infringement of Amarin’s U.S. Patent
No. 8,663,662, filed in federal court in Delaware in March 2014), Amarin shall have the right, at Amarin’s sole discretion, to grant Third Parties a license or other rights under the Amarin Intellectual Property to develop and
commercialize products other than the Product (and, for clarity, any such products shall not constitute a “Product” for purposes of this Agreement). 

9.3 Title to Trademarks. The ownership, and all goodwill from the use, of any Amarin Trademarks shall at all times vest in and
inure to the benefit of Amarin. The ownership and all goodwill from the use of any Kowa Trademarks shall at all times vest in and inure to the benefit of Kowa. Except as expressly provided in this Agreement or as mutually agreed by the Parties,
neither Party shall use the trademarks of the other Party for any purpose. 

  
 33 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 9.4 Protection of Trademarks. The Parties agree to take
reasonable actions at the cost and expense of Amarin, as provided in this Section 9.4, in the name of Amarin, to protect the Amarin Trademarks against any Third Party who either infringes the Amarin Trademarks or brings a Claim against either
or both of the Parties for infringement of the Third Party’s trademarks in relation to the use of the Amarin Trademarks. Each Party shall give notice to the other of any infringement of, or challenge to, the validity or enforceability of the
Amarin Trademarks promptly after learning of such infringement or challenge. If Amarin institutes an action against Third Party infringers or takes action to defend the Amarin Trademarks, Kowa shall cooperate fully with Amarin. Any recovery obtained
by Amarin as a result of such proceeding or other actions, whether obtained by settlement or otherwise, shall be retained by Amarin except that Amarin shall pay to Kowa any reasonable Out-of-Pocket Expenses incurred by Kowa relating to such
cooperation. Kowa shall not have any right to institute any action to defend or enforce the Amarin Trademarks. 
 ARTICLE 10

 CONFIDENTIALITY 

10.1 Disclosure of Know-How. To the extent that one Party has disclosed, or in the future discloses, to the other Party any
Know-How or other intellectual property of such Party or its Affiliates, the receiving Party shall not acquire any ownership rights in such Know-How or other intellectual property by virtue of this Agreement. 

10.2 Confidential Information. Amarin and Kowa shall neither use nor disclose to Third Parties any confidential information
received from the other Party or otherwise developed or obtained (including prior to the Term, during the Term, or during any period in which the Parties have audit rights hereunder) by either Party in the performance of activities in furtherance of
this Agreement (“Confidential Information”) without first obtaining the written consent of the disclosing Party, except as may be otherwise provided in, or required for a Party to fulfill its obligations or exercise its rights under
this Agreement. Any and all information and materials disclosed, whether by one Party to the other Party or otherwise, pursuant to that certain Confidentiality Agreement between Kowa Research Institute, Inc. (an Affiliate of Kowa) and Amarin
Corporation plc (an Affiliate of Amarin) dated August 31, 2009 (the “Confidentiality Agreement”) shall be deemed Confidential Information disclosed pursuant to this Agreement. The Parties shall take reasonable measures to
assure that no unauthorized use or disclosure is made by others to whom access to such Confidential Information is granted. If either Party is required by Applicable Law to disclose any of the Confidential Information of the other Party it shall be
permitted to do so; provided, that it shall first notify the disclosing Party in writing and shall permit the disclosing Party to contest the disclosure requirement at its sole expense. The Party required to make the legal disclosure shall fully
cooperate with the disclosing Party in order to limit such disclosure to the extent legally permissible. Notwithstanding the foregoing, the confidentiality obligations contained in this Section 10.2 shall not apply to such information that:

 (a) is or becomes a matter of public knowledge (other than by breach of this Agreement by the receiving Party), provided, information
shall not be deemed to be public knowledge by reason of its having been filed with the FDA or any other regulatory authority except to the extent available for public inspection or subject to disclosure under the Freedom of Information Act or
comparable state statutes; 

  
 34 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 (b) the receiving Party can establish by competent evidence was already
known to it or was in its possession at the time of disclosure; 
 (c) is disclosed to the receiving Party by a Third Party having the right
to do so; or 
 (d) is independently developed by or on behalf of the receiving Party, without the aid, use or application of the
Confidential Information, as evidenced by contemporaneously created written records of such receiving Party. 
 10.3 Disclosure to
Affiliates. Nothing in this Agreement shall be construed as preventing either Party from disclosing any Confidential Information received from the other to an Affiliate of the receiving Party which is necessary for the purposes of enabling
the receiving Party to fulfill its obligations under this Agreement; provided, the receiving Party shall be responsible for breaches of the confidentiality obligations contained in this ARTICLE 10 by such Affiliate. 

10.4 Press Releases and Disclosure. 

10.4.1 Initial Press Release. The Parties shall reasonably agree regarding a public announcement with respect to the execution
of this Agreement.  
 10.4.2 Subsequent Press Releases. 

(a) Kowa may not make any subsequent press release or public announcements regarding this Agreement, the Product, Amarin or any matter covered
by this Agreement, without the prior written consent of Amarin. In the event that Kowa believes it is required to issue a press release or make any other public announcement to comply with Applicable Law and Amarin does not believe such public
announcement is so required, Kowa may only issue such press release if (a) it obtains an opinion of legal counsel, from a reputable law firm approved by Amarin, that it is required to make such disclosure to comply with Applicable Law, and
(b) after receiving such opinion, provides the text of such planned disclosure to Amarin no less than [***] prior to disclosure, and has incorporated all reasonable comments of Amarin regarding such disclosure. 

(b) Amarin may publicly disclose without violation of this Agreement, such terms of this Agreement as are, on the advice of Amarin’s
counsel, required by the rules and regulations of the SEC or The NASDAQ Stock Market, Inc.; provided, that Amarin shall advise Kowa of such intended disclosures and provide Kowa with reasonable opportunity to request that Amarin seek confidential
treatment of such disclosures to be filed with the SEC. Subject to the immediately preceding sentence, Amarin shall consult with Kowa, and Kowa shall have the right to review and comment with respect to the redaction of the terms of this Agreement
or Kowa’s Confidential Information as part of the confidential treatment request to the SEC. After release of the press release announcing this Agreement and excluding any public disclosures of the terms of this Agreement that are authorized by
the preceding sentences, if Amarin desires to make a public announcement concerning the material terms of this Agreement, milestones achieved under this Agreement or Kowa’s Confidential Information, then Amarin shall give reasonable prior
advance notice of the proposed text of such announcement to Kowa for its prior review and 

  
 35 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 
approval (except as otherwise provided herein), such approval not to be unreasonably withheld, conditioned or delayed; provided, that Kowa shall provide its comments, if any, within [***] (or
[***] in the event Amarin is required to make such disclosure pursuant to Applicable Laws or stock exchange rules) after receiving the public announcement for review (and failure for Kowa to provide comments within such time period shall be deemed
to constitute Kowa’s consent to such public announcement). In relation to Kowa’s review of such an announcement, Kowa may make specific, reasonable comments on such proposed press release or other public disclosure within the prescribed
time for commentary. Amarin shall not be required to seek the permission of Kowa to disclose any information already disclosed or otherwise in the public domain, provided such information remains accurate. 

ARTICLE 11 

REPRESENTATIONS, WARRANTIES, COVENANTS AND INDEMNIFICATION 

11.1 Representations and Warranties of both Parties. Each Party represents and warrants as of the Effective Date
that: 
 (a) It has the corporate power and authority to execute and deliver this Agreement and to perform its obligations hereunder,
and the execution, delivery and performance of this Agreement has been duly and validly authorized and approved by proper corporate action on the part of such Party. Assuming due authorization, execution and delivery on the part of the other Party,
this Agreement constitutes a legal, valid and binding obligation of such Party, enforceable against such Party, in accordance with its terms. 

(b) The execution and delivery of this Agreement by it and the performance by it contemplated hereunder will not violate any Applicable Laws.

 (c) To its knowledge, it is in compliance in all material respects with all material Applicable Laws applicable to the subject matter of
this Agreement. 
 (d) It is not a party to any agreement or arrangement with any Third Party or under any obligation or restriction
(including any outstanding order, judgment or decree of any court or administrative agency) which in any way limits or conflicts with its ability to fulfill any of its obligations under this Agreement. 

(e) As of the Effective Date and during the Term, neither it nor its Affiliates nor any of their respective directors, officers, employees, or
consultants, and, to its knowledge based upon reasonable inquiry, any Third Party (and its directors, officers, employees and consultants), in each case whose responsibilities involve the Promotion and Detailing of the Product hereunder: 

(i) are debarred under Section 306(a) or 306(b) of the Act; 

(ii) have been charged with, or convicted of, any felony or misdemeanor under Applicable Laws related to any of the following: (A) the
development or approval of any drug product or the regulation of any drug product under the Act; (B) a conspiracy to commit, aid or abet the development or approval of any drug product or regulation

  
 36 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 
of any drug product; (C) health care program-related crimes (involving Medicare or any State health care program); (D) patient abuse, controlled substances, bribery, payment of illegal
gratuities, fraud, perjury, false statement, racketeering, blackmail, extortion, falsification or destruction of records; (E) interference with, obstruction of an investigation into, or prosecution of, any criminal offense; or (F) a
conspiracy to commit, aid or abet any of these listed felonies or misdemeanors; or 
 (iii) is excluded, suspended or debarred from
participation, or otherwise ineligible to participate, in any federal or state health care programs (including convicted of a criminal offense that falls within the scope of 42 U.S.C. §1320a-7 but not yet excluded, debarred, suspended, or
otherwise declared ineligible), or excluded, suspended or debarred from participation, or otherwise ineligible to participate, in any Federal procurement or nonprocurement programs. 

(f) Each Party will notify the other Party immediately, but in no event later than five (5) days, after knowledge of any exclusion,
debarment, suspension or other ineligibility set forth in Section 11.1(e)(iii) occurring during the Term, or if such Party concludes based on its good faith business judgment that a pending action or investigation is likely to lead to the
exclusion, debarment, suspension or other ineligibility of such Party. 
 (g) Each Party at its own expense hereby covenants that it shall,
as part of the pre-hiring or pre-contracting process, screen against Exclusion Lists (as defined below) all of its directors, officers, employees, consultants, and any Third Party (and those of such Third Party’s directors, officers, employees
and consultants that are known to such Party), in each case that such Party hires or engages whose responsibilities, to such Party’s knowledge based on reasonable inquiry, involve the Promotion or Detailing of the Product as authorized by this
Agreement, and will conduct such screens on an annual basis thereafter. Upon request by a Party, the other Party shall certify the results of such screening to the requesting Party. For purposes of this Agreement, “Exclusion Lists” include
at a minimum: (i) the HHS/OIG List of Excluded Individuals/Entities (available through the Internet at http://www.oig.hhs.gov) or any successor list; and (ii) the General Services Administration’s List of Parties Excluded from Federal
Programs (available through the Internet at http://www.epls.gov) or any successor list. 
 (h) It has provided or made available, when
requested by the other Party to conduct its due diligence review, any and all documents and communications in its possession from and to the FDA or any other Governmental Authority, or prepared by the FDA or any other Governmental Authority, that
may bear on compliance with the requirements of the FDA or any other Governmental Authority, including any notice of inspection, inspection report, warning letter, deficiency letter, or similar communication. In connection with the foregoing, each
Party represents and warrants to the other that it is not subject, as of the Effective Date, to any corporate integrity agreement(s) and each Party further covenants that it shall promptly notify the other Party in the event that it becomes subject
to a corporate integrity agreement at any time during the Term. 
 (i) Neither it nor any of its Affiliates has received any oral or written
communication (including any warning letter, untitled letter, or similar notices) from the FDA and there is no action pending or, to its knowledge, threatened (including any prosecution, injunction, seizure, civil fine, suspension or recall), in
each case alleging that it or any of its Affiliates is not currently materially in compliance with any and all Applicable Laws implemented by the FDA. 

  
 37 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 (j) To its knowledge, it nor any of its Affiliates or any of their
respective officers, employees or agents has made an untrue statement of a material fact to the FDA or other Governmental Authority or failed to disclose a material fact required to be disclosed to the FDA or other Governmental Authority; and 

(k) There is no material matter known to it as of the Effective Date which has not been disclosed by it to the other Party concerning the
safety or efficacy of the Product. 
 11.2 Additional Representations, Warranties and Covenants of Amarin. Amarin additionally
represents, warrants and covenants as of the Effective Date that: 
 (a) Amarin has no knowledge that the Promotion or Detailing of
the Product in the Territory under this Agreement will infringe a claim in an issued patent of a Third Party, but nothing in this Agreement shall be construed as a warranty or representation that the Promotion or Detailing of the Product pursuant to
this Agreement is or will be free from infringement of any Third Party patent. 
 (b) The Product was approved for sale by the FDA in the
United States as of July 26, 2012 for use an adjunct treatment to diet to reduce triglyceride (TG) levels in adult patients with severe (3 500 mg/dL) hypertriglyceridemia. 

(c) Amarin will maintain (or cause to be maintained in the case of manufacturing facilities of Third Parties) continuously in full force and
effect during the Term all Regulatory Approvals pertaining to the Product that are necessary for Amarin to meet its obligations hereunder, including the approval referred to in Section 11.2(b) above, and that are necessary for the lawful
manufacturing and sale of the Product for human therapeutic use in the Field in the Territory. 
 (d) Amarin owns the rights it purports to
grant to Kowa under this Agreement. 
 11.3 Additional Representations, Warranties and Covenants of Kowa. Kowa additionally
represents, warrants and covenants as of the Effective Date that: 
 (a) Kowa is not commercializing, marketing, Promoting, selling,
offering for sale, importing and/or distributing, and is not undertaking any clinical development of, any Competing Product in the Territory; and 

(b) Kowa has conducted such due diligence as it believes is necessary, including having had an opportunity to ask questions of, and receive
answers from, representatives of Amarin. 

  
 38 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 11.4 Indemnification by Amarin. Amarin shall indemnify and
defend Kowa and its Affiliates and each of their respective employees, officers, directors and agents (the “Kowa Indemnitees”) from and against any and all Losses to the extent arising out of Claims of Third Parties related
to: (a) Amarin’s negligence or willful misconduct, (b) Amarin’s performance of its obligations under this Agreement, (c) breach by Amarin of this Agreement or Applicable Laws, (d) infringement or misappropriation of
Third Party intellectual property rights directly or indirectly related to the Product, (e) use of the Product, including the toxicity, carcinogenicity, immunogenicity, teratogenicity and other inherent effects of the Product, and
(f) Promotional Materials that are in violation of Applicable Laws; provided, however, that Amarin’s obligations pursuant to this Section 11.4 shall not apply (i) to the extent such claims or suits result from the negligence or
willful misconduct of any of the Kowa Indemnitees, or (ii) with respect to Losses for which Kowa is obligated to indemnify Amarin pursuant to Section 11.5. 

11.5 Indemnification by Kowa. Kowa shall indemnify and defend Amarin and its Affiliates and each of their respective agents,
employees, officers and directors (the “Amarin Indemnitees”) against any and all Losses to the extent arising out of Claims of Third Parties (except as provided in clauses (d) and (e)) related to: (a) Kowa’s
negligence or willful misconduct, (b) Kowa’s performance of its obligations under this Agreement, (c) breach by Kowa of this Agreement or Applicable Laws, (d) Kowa’s use, in violation of Applicable Laws, of Promotional
Materials that comply with Applicable Laws, (e) any claims for benefits that any Kowa Sales Representative may make for performance under this Agreement under or with respect to any Benefit Plan, and (f) any payment or obligation to make a
payment to any Kowa Sales Representative for performance under this Agreement relating in any way to any compensation or benefits or the payment or withholding of any contributions, payroll taxes, or any other payroll-related item by or on behalf of
Kowa or any of the Kowa Sales Representative (even if it is subsequently determined by any court or any governmental agency that any such Kowa Sales Representative may be a common law employee of Amarin or otherwise entitled to such benefits);
provided, however, that Kowa’s obligations pursuant to this Section 11.5 shall not apply (i) to the extent that such claims or suits result from the negligence or willful misconduct of any of the Amarin Indemnitees, or (ii) with
respect to Losses for which Amarin is obligated to indemnify Kowa pursuant to Section 11.4. 
 11.6 Indemnification
Procedures. The obligations to indemnify and defend set forth in Sections 11.4 and 11.5 shall be contingent upon the Party seeking indemnification (the “Indemnitee”): (a) notifying the indemnifying Party of a claim,
demand or suit within fifteen (15) Business Days of receipt of same (provided, however, that an Indemnitee’s failure or delay in providing such notice shall not relieve the indemnifying Party of its indemnification obligation except to the
extent the indemnifying Party is prejudiced thereby), (b) allowing the indemnifying Party and/or its insurers the right to assume direction and control of the defense of any such Claim, (c) using diligent efforts to cooperate with the
indemnifying Party and/or its insurers in the defense of such Claim at the indemnifying Party’s expense, and (d) agreeing not to settle or compromise any Claim without prior written authorization of the indemnifying Party. Indemnitee shall
have the right to participate in the defense of any such Claim referred to in this Section 11.6 utilizing attorneys of its choice, at its own expense; provided, however, that the indemnifying Party shall have full authority and control to
handle any such Claim. The indemnifying Party shall have the right to settle or compromise any action or otherwise seek to terminate any pending or threatened action for which indemnity may be sought hereunder (whether or not any indemnified Party
is a party thereto); provided, that such settlement, compromise or termination includes an unconditional release of and no admission of liability by each indemnified Party from all liability in respect of such Claim. 

  
 39 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 11.7 Limitation of Liability. NOTWITHSTANDING ANY OTHER
PROVISION CONTAINED HEREIN, UNLESS RESULTING FROM A PARTY’S FRAUDULENT BEHAVIOR, IN NO EVENT SHALL AMARIN OR KOWA BE LIABLE TO THE OTHER OR ANY OF THE OTHER’S AFFILIATES FOR ANY CONSEQUENTIAL, INCIDENTAL, INDIRECT, SPECIAL, PUNITIVE OR
EXEMPLARY DAMAGES (INCLUDING LOST PROFITS, BUSINESS OR GOODWILL) SUFFERED OR INCURRED BY SUCH OTHER PARTY OR ITS AFFILIATES IN CONNECTION WITH A BREACH OR ALLEGED BREACH OF THIS AGREEMENT. THE FOREGOING SENTENCE SHALL NOT LIMIT THE OBLIGATIONS OF
EITHER PARTY TO INDEMNIFY THE OTHER PARTY FROM AND AGAINST THIRD PARTY CLAIMS UNDER SECTION 11.4 OR SECTION 11.5. 
 11.8
Disclaimer of Warranty. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN THIS AGREEMENT, AMARIN AND KOWA MAKE NO REPRESENTATIONS AND GRANT NO WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR
OTHERWISE, AND AMARIN AND KOWA EACH SPECIFICALLY DISCLAIM ANY OTHER REPRESENTATIONS AND WARRANTIES, WHETHER WRITTEN OR ORAL, EXPRESS, STATUTORY OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE OR PURPOSE
OR ANY WARRANTY AS TO THE VALIDITY OF ANY PATENTS OR THE NON-INFRINGEMENT OF ANY INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES (which disclaimer pertaining to non-infringement shall not mitigate Amarin’s obligations under
Section 11.4(d)). 
 11.9 Insurance. During the Term, each Party shall obtain and maintain, at its sole cost and
expense, general liability insurance and product liability insurance (including any self-insured arrangements) in amounts that are reasonable and customary in the United States pharmaceutical and biotechnology industry for companies engaged in
comparable activities. It is understood and agreed that this insurance shall not be construed to limit either Party’s liability with respect to its indemnification obligations hereunder. Each Party will, except to the extent self-insured,
provide to the other Party upon request a certificate evidencing the insurance such Party is required to obtain and keep in force under this Section 11.9. Without limiting the foregoing, Amarin does not and will not maintain or procure any
worker’s compensation, healthcare, or other insurance for or on behalf of any Kowa Sales Representative, all of which shall be Kowa’s sole responsibility. For clarity, the insurance requirements of this Section 11.9 shall not be
construed to create a limit of either Party’s liability with respect to its indemnification obligations under this ARTICLE 11. 

ARTICLE 12 
 TERM AND
TERMINATION 
 12.1 Term. The term of this Agreement shall commence on the Effective Date and end on December 31,
2018 (the “Initial Term”). After the Initial Term, and subject to Gross Sales during Year 2018 exceeding [***], this Agreement may be extended by mutual agreement of the Parties for an additional two (2) year period (the
Initial Term and such renewal term, if any, are collectively referred to as the “Term”). For clarity, in the event that the Initial Term is extended in accordance with this Section 12.1, then Amarin shall continue to pay Kowa a
Co-Promote Fee at a rate to be agreed as part of the Parties’ mutual decision to extend the Term. 

  
 40 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 12.2 Early Termination by Mutual Agreement. The Parties
may, at each Party’s sole discretion, mutually agree in writing to terminate this Agreement following the [***] of the Effective Date. 

12.3 Reciprocal Early Termination Rights. Each Party shall have the right to terminate this Agreement before the end of the Term
as follows: 
 (a) by either Party upon written notice to the other Party in the event of a material breach of this Agreement by such
other Party where such breach is not cured within ninety (90) days following such other Party’s receipt of written notice of such breach; 

(b) by either Party on five (5) days written notice to the other Party upon (A) the making or seeking to make or arrange an
assignment for the benefit of creditors of such other Party, (B) the appointment of a receiver of such other Party’s property that is not discharged within ninety (90) days, or (C) the stockholders or equity holders of such other
Party approve a plan of complete liquidation of such other Party, other than to an Affiliate of such other Party; 
 (c) by either Party on
five (5) days written notice to the other Party due to a Force Majeure event in accordance with Section 15.4 that persists for ninety (90) days or more; or 

(d) by either Party on five (5) days written notice to the other Party in the event of (A) the filing of federal or state criminal
charges against the such Party or one of such other Party’s directors, officers or senior management employees relating to such person’s activities on behalf of such other Party or (B) the felony conviction of such other Party or one
of such other Party’s directors, officers or senior management employees. 
 12.4 Early Termination Due to Change of
Control. 
 12.4.1 Termination. In the event of a Change of Control of either Party during the Term, the Party
experiencing the Change of Control shall deliver a written notice of such Change of Control to the other Party within thirty (30) days of the Change of Control event. At any time within sixty (60) days after receipt of the notice of the
Change of Control, including as part of the notice of such Change of Control, either Party (or its successor) may terminate this Agreement by written notice to the other Party (or its successor). 

12.4.2 Alternative to Termination. Without limiting the foregoing, in the event that the Party not undergoing the Change of
Control does not exercise its right to terminate this Agreement in accordance with Section 12.4.1, then such Party shall have the right to require the Party experiencing the Change of Control (including its Affiliates following such Change of
Control) to adopt procedures as reasonably requested by the Party not undergoing the Change of Control to prevent the disclosure of such Party’s Confidential Information beyond personnel having access to and knowledge of such Confidential
Information prior to the Change of Control and to control the dissemination of such Party’s Confidential Information disclosed after the Change of Control. The purposes of such procedures shall be to strictly limit such disclosures to only
those personnel having a need to know Confidential Information in order for the Party experiencing the Change of Control to perform its obligations under this Agreement and to prohibit the use of Confidential Information for competitive reasons.

  
 41 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 12.5 Early Termination Due to Deficient Sales. Each Party
shall have the right to terminate this Agreement, following [***], on [***] advance written notice to the other Party in the event that Gross Sales of the Product in the Field in the Territory for the [***] did not exceed the minimum thresholds set
forth below; provided, that such right to terminate must be exercised by a Party within [***] of Amarin providing to Kowa the report required by Section 5.4.1 regarding the fourth Quarter of such previous Year. For clarity, (i) this right
to terminate shall be available each Year during the Term to each Party but must be exercised within such [***] period, (ii) the terminating Party shall have performed [***] required to be performed by such Party, and expended [***] required to
be spent by such Party, pursuant to Section 4.4 for the previous Year and (iii) the failure to reach the minimum Gross Sales Thresholds set forth below shall not in and of itself be deemed to be a breach of this Agreement. 

[***] 
 12.6 Early
Termination by Amarin. 
 12.6.1 Related Product. Amarin shall have the right to terminate this Agreement upon
sixty (60) days’ notice in the event that Kowa is commercializing or otherwise promoting or detailing any product (other than the Product) that, despite its approved label, is being used to reduce triglyceride levels in fifty percent
(50%) or more of its prescribed applications according to NDTI data. 
 12.6.2 Diligence. Amarin shall have the
right to terminate this Agreement immediately upon written notice to Kowa in accordance with Section 4.4.1. 
 12.7 Early
Termination by Kowa. 
 12.7.1 [***]. Kowa shall have the right to terminate this Agreement upon [***] written notice
to Amarin in order to make, have made, use, develop, market, promote, co-promote, sell, offer for sale, import, distribute and/or exploit in all regards [***]; provided, that (i) such notice may not be provided prior to [***], and (ii) as
a condition precedent to Kowa’s right to terminate pursuant to this Section 12.7.1, Kowa must have provided Amarin with the notice regarding filing for Regulatory Approval for [***] as required by Section 2.2.2. 

12.7.2 Diligence. Kowa shall have the right to terminate this Agreement immediately upon written notice to Amarin in accordance
with Section 4.4.2. 
 ARTICLE 13 

RIGHTS AND DUTIES UPON EXPIRATION OR TERMINATION 

13.1 Effects of Termination. Upon the effective date of expiration or termination of this Agreement, (a) all rights granted
to Kowa hereunder shall immediately terminate and Kowa shall immediately cease all Promotion and Detailing activities with respect to the Product, (b) 

  
 42 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 
Kowa, at Amarin’s direction, shall immediately return to Amarin or destroy all Promotional Materials, reports and other tangible items provided by or on behalf of Amarin to Kowa or otherwise
developed or obtained by Kowa (including all data, reports and materials generated by Kowa relating to the Promotion and Detailing of the Product) pursuant to the terms of this Agreement (and at the request of Amarin, Kowa shall certify destruction
of such materials if Kowa does not to return such materials to Amarin), (c) Kowa shall return to Amarin (or its designee), or destroy (and subject to Kowa providing Amarin appropriate documentation supporting the destruction of such Samples,
and making such documentation available upon Amarin’s reasonable request therefor) any and all Samples in Kowa’s or the Kowa Sales Representatives’ possession, and (d) each Party shall, at the other Party’s direction, either
return to the other Party or destroy all Confidential Information of the other Party (provided that such Party may retain one copy of such Confidential Information of the other Party for archival purposes). 

13.2 Survival; Continuing Obligations. In addition to any provisions of this Agreement that by their express terms shall survive
its expiration or termination, the following provisions shall survive any expiration or termination of this Agreement: Sections 2.2, 2.3, 2.4, 4.3.6, 4.9, 4.13, 5.7, 7.1, 7.2, 7.5.5, 7.8, 9.1, 10.2, 11.7, and 11.8 (provided, that Sections 2.2, 2.3,
2.4, 4.13, 7.5.5 and 7.8 shall only survive for the periods set forth in each such respective provision), and Articles 8, 13 and 14 (provided, that Article 8 shall only survive for the period set forth in such provision), as well as any provisions
required to interpret and enforce the Parties’ rights and obligations under this Agreement shall survive this Agreement, but only to the extent required for the full observation and performance of this Agreement. 

13.3 Remedies. Termination of this Agreement, in accordance with its provisions, shall not limit the remedies that may be
available to either Party in law or equity; provided, that, for clarity, the rightful exercise of a right to terminate under this Agreement shall not be, in and of itself, the basis for a claim by the non-terminating Party. 

13.4 Continuing Detailing Obligations. For clarity, Kowa shall continue to perform its Detailing and other obligations until the
effective date of termination. 
 13.5 Tail Period Payments. During the Tail Period, Amarin shall pay Kowa the
applicable Tail Period Payments as follows: 
 (a) the Co-Promote Fee Tail Payments shall be paid [***] on a [***] during the period
indicated in Section 5.3.1; and 
 (b) the Net Sales Tail Payment shall be paid [***] in the applicable sub-clause of
Section 5.3.2. 
 For clarity, if this Agreement is terminated for any reason other than those reasons specifically set forth in Section 5.3.1 or
Section 5.3.2, then Kowa shall not be entitled to receive any Tail Period Payments. 

  
 43 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 ARTICLE 14 

GOVERNING LAW AND DISPUTE RESOLUTION 

14.1 Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the New York, excluding the
choice of law rules thereof. 
 14.2 Dispute Resolution. The Parties recognize that disputes as to certain matters may
from time to time arise during the Term which relate to either Party’s rights and/or obligations hereunder. It is the objective of the Parties to establish procedures to facilitate the resolution of disputes arising under this Agreement in an
expedient manner by mutual cooperation and without resort to litigation. To accomplish this objective, the Parties agree to follow the procedures set forth in this ARTICLE 14 if and when a dispute arises under this Agreement. 

14.2.1 Referred From Committee. Any dispute, controversy or difference arising from the JSC pursuant to ARTICLE 3 shall be
resolved in accordance with Section 3.1.4. 
 14.2.2 Arising Between the Parties. Other than any dispute, controversy or
difference which may arise from the JSC as described in Section 14.2.1, any disputes, controversies or differences which may arise between the Parties out of or in relation to or in connection with this Agreement, including any alleged failure
to perform, or breach, of this Agreement, or any issue relating to the interpretation or application of this Agreement, then upon the request of either Party, the Parties agree to meet and discuss in good faith a possible resolution thereof, which
good faith efforts shall include at least one in-person meeting between the chief executive officers of each Party. If the matter is not resolved within thirty (30) days following the request for discussions, either Party may then invoke the
provisions of Section 14.3. 
 14.3 Arbitration. Any dispute, controversy or claim arising out of or relating to the validity,
construction, interpretation, enforceability, breach, performance, application or termination of this Agreement that is not resolved pursuant to Section 14.2.2, shall be settled by binding arbitration administered by JAMS pursuant to its
Comprehensive Arbitration Rules and Procedures of JAMS then in effect (the “JAMS Rules”), except as otherwise provided herein. The arbitration shall be governed by the United States Federal Arbitration Act, 9 U.S.C. §§
1-16 (the “Federal Arbitration Act”), to the exclusion of any inconsistent state laws. The United States Federal Rules of Civil Procedure shall govern discovery and the rules of evidence for the arbitration. The arbitration will be
conducted in New York, New York, and the Parties consent to the personal jurisdiction of the United States federal courts, for any case arising out of or otherwise related to this arbitration, its conduct and its enforcement. Any situation not
expressly covered by this Agreement shall be decided in accordance with the JAMS Rules. 
 14.3.1 Arbitrator. The
arbitrator shall be one (1) neutral, independent and impartial arbitrator selected from a pool of retired federal judges or magistrates to be presented to the Parties by JAMS. Failing the agreement of the Parties as to the selection of the
arbitrator within thirty (30) days, the arbitrator shall be appointed by JAMS in accordance with the JAMS Rules. 
 14.3.2
Decision. The power of the arbitrator to fashion procedures and remedies within the scope of this Agreement is recognized by the Parties as essential to the success of the arbitration process. The arbitrator shall not have the authority to
fashion remedies which would 

  
 44 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 
not be available to a federal judge hearing the same dispute. The arbitrator is encouraged to operate on this premise in an effort to reach a fair and just decision. Reasons for the
arbitrator’s decisions should be set forth in accordance with the JAMS Rules. Such a written decision shall be rendered by the arbitrator following a full comprehensive hearing, no later than twelve (12) months following the selection of
the arbitrator as provided for in Section 14.3.1. 
 14.3.3 Award. Any award shall be promptly paid in Dollars free of
any tax, deduction or offset; and any costs, fees or taxes incident to enforcing the award shall, to the maximum extent permitted by Applicable Law, be charged against the Party resisting enforcement. If as to any issue the arbitrator should
determine under the Applicable Law that the position taken by a Party is in violation of the standards of Rule 11(b) of the Federal Rules of Civil Procedure, the arbitrator shall also award an appropriate allocation of the adversary’s
reasonable attorney fees, costs and expenses to be paid by the offending Party, the precise sums to be determined after a bill of attorney fees, expenses and costs consistent with such award has been presented following the award on the merits. Each
Party agrees to abide by the award rendered in any arbitration conducted pursuant to this ARTICLE 14, and agrees that, subject to the Federal Arbitration Act, judgment may be entered upon the final award in any court of competent jurisdiction and
that other courts may award full faith and credit to such judgment in order to enforce such award. The award shall include interest from the date of the award until paid in full, at a rate fixed by the arbitrator and the arbitrator may, in his or
her discretion, award pre-judgment interest. With respect to money damages, nothing contained herein shall be construed to permit the arbitrator or any court or any other forum to award punitive or exemplary damages. By entering into this agreement
to arbitrate, the Parties expressly waive any claim for punitive or exemplary damages. 
 14.3.4 Costs. Except as set forth in
Section 14.3.3, each Party shall bear its own legal fees. The arbitrator shall assess his or her costs, fees and expenses against the Party losing the arbitration unless he or she believes that neither Party is the clear loser, in which case
the arbitrator shall divide his or her fees, costs and expenses according to his or her sole discretion. 
 14.3.5 Injunctive
Relief. Provided a Party has made a sufficient showing under the rules and standards set forth in the Federal Rules of Civil Procedure and applicable case law, the arbitrator shall have the freedom to invoke, and the Parties agree to abide by,
injunctive measures after either Party submits in writing for arbitration claims requiring immediate relief. Additionally, nothing in this ARTICLE 14 will preclude either Party from seeking equitable relief or interim or provisional relief from a
court of competent jurisdiction, including a temporary restraining order, preliminary injunction or other interim equitable relief, concerning a dispute either prior to or during any arbitration if necessary to protect the interests of such Party or
to preserve the status quo pending the arbitration proceeding. 
 14.3.6 Confidentiality. The arbitration proceeding shall be
confidential and the arbitrator shall issue appropriate protective orders to safeguard each Party’s Confidential Information. Except as required to comply with Applicable Laws, including rules and regulations promulgated by the SEC, The NASDAQ
Stock Market or any securities exchanges, no Party shall make (or instruct the arbitrator to make) any public announcement with respect to the proceedings or decision of the arbitrator without prior written consent of the other Party. The existence
of any dispute submitted to arbitration, and the award, shall be kept in confidence by the Parties and the arbitrator, except as required in connection with the enforcement of such award or as otherwise required by Applicable Law. 

  
 45 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 14.3.7 Survivability. Any duty to arbitrate under this
Agreement shall remain in effect and be enforceable after termination of this Agreement for any reason. 
 ARTICLE 15 

MISCELLANEOUS 
 15.1
Engagement of Contract Sales Force or Subcontracting. 
 15.1.1 Kowa. Kowa shall not engage a contract sales
organization to fulfill its obligations under this Agreement nor shall it subcontract any of its obligations under this Agreement, except its audit rights, to a Third Party or to its Affiliates, without the prior written consent of Amarin. 

15.1.2 Amarin. Amarin may engage a contract sales organization to perform Promotion and Detailing in the Territory[***]. 

15.2 Assignment. Neither Party shall assign or transfer its rights or obligations under this Agreement, except to an Affiliate
(including entities that become Affiliates following a Change of Control), without the prior written consent of the other Party. In the event of any permitted assignment, the assigning or transferring Party must confirm to the other Party in writing
that it will remain fully liable for all obligations under this Agreement as if such assignment or transfer had not occurred. Any attempted assignment or transfer in contravention of this Section 15.2 shall be of no legal effect. 

15.3 Notices. Any notice, request, approval or other document required or permitted to be given under this Agreement shall be in
writing and shall be deemed to have been given when delivered in person, or sent by overnight courier service, postage prepaid, or sent by certified or registered mail, return receipt requested to the following addresses of the Parties and to the
attention of the persons identified below (or to such other address, addresses or persons as may be specified from time to time in a written notice). Any notices given pursuant to this Agreement shall be deemed to have been given and delivered upon
the earlier of (a) if sent by overnight courier service, on the date when received at the address set forth below as proven by a written receipt from the delivery service verifying delivery, or (b) if sent by certified or registered mail,
three (3) Business Days after mailed by certified or registered mail postage prepaid and properly addressed, with return receipt requested, or (c) if delivered in person, on the date of delivery to the address set forth below as proven by
written signature of the recipient. 
  

			
	 If to Kowa:
  

Name: Kowa Pharmaceuticals America, Inc.
 Street: 530 Industrial
Park Boulevard
 City/State: Montgomery, AL 36117
 Country:
U.S.A
 Attn: Chief Executive Officer and Chief Operating Officer, respectively
	  	 With a copy to:
  

Name: Foley & Lardner LLP
 Street: 3579 Valley Centre Drive,
Suite 300
 City/State: San Diego, CA 92138
 Country: U.S.A.

Attn: Richard A. Kaufman

  
 46 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
  

			
	 If to Amarin Pharma:
  

Name: Amarin Pharma, Inc.
 Street: 1430 Route 206, Suite 101

City/State: Bedminster, NJ 07921
 Country: U.S.A.

Attn: Chief Executive Officer
	  	 With a copy to:
  

Name: Amarin Pharma, Inc.
 Street: 1430 Route 206, Suite 101

City/State: Bedminster, NJ 07921
 Country: U.S.A.

Attn: General Counsel

  

			
	 If to Amarin Ireland:
  

Name: Amarin Pharmaceuticals Ireland Limited
 Street: 88 Harcourt
Street, Dublin 2, Co
 City/State: Dublin
 Country: Ireland

Attn: Chief Executive Officer
	  	 With a copy to:
  

Name: Amarin Pharma, Inc.
 Street: 1430 Route 206, Suite 101

City/State: Bedminster, NJ 07921
 Country: U.S.A.

Attn: Chief Executive Officer and General Counsel, respectively

  

			
	 Any notice to Amarin Pharma and/or Amarin Ireland shall also include a copy to:

 
 Name: Morgan, Lewis & Bockius, LLP

Street: 502 Carnegie Center
 City/State: Princeton, NJ 08540

Country: U.S.A
 Attn: Randall B. Sunberg
	  	 Any notice to Amarin Pharma and/or Amarin Ireland shall also include a copy to:

 
 Name: Goodwin Procter LLP

Street: 53 State Street
 City/State: Boston, MA 02109

Country: U.S.A.
 Attn: Michael Bison

 15.4 Force Majeure. If the performance of any part of this Agreement by either Party, or of any
obligation under this Agreement, is prevented, restricted, interfered with or delayed by reason of a Force Majeure affecting the Party liable to perform, unless conclusive evidence to the contrary is provided, the Party so affected shall, upon
giving written notice to the other Party, be excused from such performance to the extent of such Force Majeure, provided that the affected Party shall use its Commercially Reasonable Efforts to avoid or remove such causes of nonperformance and shall
continue performance with the utmost dispatch whenever such Force Majeure ceases. When such circumstances arise, the Parties shall discuss what, if any, modification of the terms of this Agreement may be required in order to arrive at an equitable
solution. 
 15.5 No Partnership or Joint Venture. Amarin and Kowa shall be independent contractors and the
relationship between the Parties hereunder shall not constitute a partnership, joint venture or agency. Neither Amarin nor Kowa shall have the authority to make any statements, representations or commitments of any kind, or to take any action, which
shall be binding on the other, without the prior written consent of such other Party to do so. 

  
 47 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 15.6 No Waiver Of Breach. The failure of either Party at
any time or times to require performance of any provision hereof shall in no manner affect its rights at a later time to enforce the same. No waiver by either Party of any condition or term in any one or more instances shall be construed as a
further or continuing waiver of such condition or term or of another condition or term. 
 15.7 Severability. In the
event that any portion of this Agreement is held illegal, void or ineffective, the remaining portions of this Agreement shall remain in full force and effect. If any of the terms or provisions of this Agreement are in conflict with any Applicable
Law, then such terms or provisions shall be deemed to be modified to conform with such Applicable Law to the extent necessary in order that such terms or provisions be valid and enforceable and such amendment shall apply only with respect to the
operation of such terms or provisions in the particular jurisdiction in which such declaration is made or, if such modification is not feasible, then such terms and provisions shall be deemed to be inoperative to the extent that such terms or
provisions conflict with Applicable Law. In the event that the terms and conditions of this Agreement are materially altered as a result of this Section 15.7, the Parties shall renegotiate the terms and conditions of this Agreement to resolve
any inequities and to achieve the original intent of the Parties. 
 15.8 Entire Agreement. This Agreement and all
Schedules attached hereto, and including the safety agreement referred to in Section 7.6.3, shall constitute the entire agreement between the Parties relating to the subject matter hereof and thereof and shall supersede all previous writings
and understandings including the Confidential Disclosure Agreement. No terms or provisions of this Agreement shall be varied or modified by any prior or subsequent statement, conduct or act of either of the Parties, except that the Parties may amend
this Agreement by written instruments specifically referring to and executed in the same manner as this Agreement. 
 15.9
Interpretation. The words “include,” “includes” and “including” shall be deemed to be followed by the phrase “without limitation.” All references herein to Articles, Sections, and Schedules shall be
deemed references to Articles and Sections of, and Schedules to, this Agreement unless the context shall otherwise require. Except as otherwise expressly provided herein, all terms of an accounting or financial nature shall be construed in
accordance with generally accepted accounting principles in the United States, as in effect from time to time. 
 15.10 Execution In
Counterparts. This Agreement may be executed in two (2) counterparts, each of which shall be deemed an original but which together shall constitute one (1) and the same instrument. A facsimile or a portable document format (PDF)
copy of this Agreement, including the signature pages, will be deemed an original. 
 [Signature page follows.] 

  
 48 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 IN WITNESS WHEREOF, the Parties, through their authorized
representatives, have executed this Co-Promotion Agreement as of the Effective Date. 
 KOWA PHARMACEUTICALS, AMERICA, INC. 

			
		
	By:	 	/s/ Benjamin Stakely
	Name:	 	Benjamin Stakely
	Title:	 	President and CEO

  

			
	AMARIN PHARMA, INC.
		
	By:	 	/s/ John F. Thero
	 Name:
 Title:
	 	 John F. Thero
 President and
CEO

  

			
	AMARIN PHARMACEUTICALS IRELAND LIMITED
		
	By:	 	/s/ Patrick O’Sullivan
	 Name:
 Title:
	 	 Patrick O’Sullivan

Director

  
 49 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 Schedule 1.14 

Amarin Trademarks* 
 [***] 

  
 Schedule
1.14 - Amarin Trademarks 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 Schedule 1.53 

Kowa Trademarks 
 [***] 

  
 Schedule
1.53 - Kowa Trademarks 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 Schedule 1.86 

Example of Sample Costs Calculation* 

[***] 

  
 Schedule
1.86 - Example of Sample Costs Calculation 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 Schedule 4.4 

PDE Adjustment Calculation Example 

Example: 
 [***] 

  
 Schedule
4.4 - PDE Adjustment Calculation Example 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 Schedule 5.2 

Co-Promote Fee 
 The percentage of Gross
Margin to be used to calculate the Co-Promote Fee may vary [***] depending whether (1) the ANCHOR Data is permitted by the FDA or otherwise under Applicable Law to be used in the Promotion of the Product, or (2) the FDA has approved the
ANCHOR Indication, and may also vary depending on the total Gross Sales, in all cases as set forth below. 
 [***] 

  
 Schedule
5.2 - Co-Promote Fee

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00230-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00230-of-00352.parquet"}]]